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iZusammenfassung
Die 12/15-Lipoxygenasen (12/15-LOXs) gehören zu einer heterogenen Klasse Lipid-
peroxidierender Enzyme, deren biologische Rolle noch nicht vollständig geklärt ist. Eine
Reihe experimenteller Daten deuten darauf hin, dass diese Enzym an Reifungs- und
Differenzierungsprozessen beteiligt sind und auch für die Pathogenese verschiedener
Erkrankungen (Asthma bronchiale, Entzündung, Atherosklerose) bedeutsam zu sein
scheinen. Die Expression von 12/15-LOXs wird in vielen Säugetierzellen durch TH2-
Zytokine reguliert und die Zytokin-induzierte Signaltransduktionskaskade verläuft über
die Aktivierung van JAK-Kinasen und STAT6. Nach einer Stimulation von A549
Lungenkarzinomzellen mit Interleukin-4 (IL-4) kommt es erst nach 12 Stunden zu einer
Hochregulation der 12/15-LOX mRNA Expression. Untersuchungen zum
Induktionsmechanismus haben gezeigt, dass Genistein, ein Hemmstoff von
Tyrosinkinasen, die Phosphorylierung von STAT6 und dessen Bindung an den Promoter
des 12/15-LOX Gens verhinderte. Damit konnte die Induktion der katalytisch aktiven
LOX geblockt werden. In Gegensatz dazu verhinderte Zykloheximid, ein spezifischer
Hemmstoff der Proteinbiosynthese, die Expression der 12/15-LOX mRNA nicht, Dieses
Ergebnis deutet darauf hin, dass die Neusynthese eines Transkriptionsfaktors im Rahmen
der IL-4 induzierten Transduktionskaskade unwahrscheinlich ist. Weiterhin wurde
beobachtet, dass IL-4 die zelluläre Histonacetyltransferase-Aktivität stark erhöhte und
dass dieser Effekt überwiegend auf die enzymatische Aktivität des (CREB-bindenden
Protein)-bindenden Proteins (CBP) zurückzuführen ist. Transfektion der Zellen mit E1A,
einem viralen Protein, welches als Hemmstoff der Histonacetyltransferase-Aktivität von
CBP/p300 bekannt ist, führte zu einer Unterdrückung der 12/15-LOX Expression.
Andererseits stimuliert Natriumbutyrat, ein Hemmstoff der Histondeacetylase, die 12/15-
LOX Synthese. Damit konnte gezeigt werden, dass die Acetylierung von Histonproteinen
und von STAT6 ein essentieller Prozesse bei der IL-4 induzierten 12/15-LOX Expression
in A549 Zellen ist. Weiterhin belegen diese Daten, dass sowohl die Phosphorylierung als
auch die Acetylierung von STAT6 an der transkriptionellen Aktivierung des 12/15-LOX
Gens beteiligt sind, obwohl beide Prozesse eine unterschiedliche Kinetik aufweisen.
STAT6 Phosphorylierung erfolgt innerhalb der ersten Stunde nach IL-4 Stimulation,
während die Acetylierungsreaktion zeitlich verzögert abläuft. Zusammenfassend kann die
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Signaltransduktionskaskade, die in A549 Zellen zur Expression der 12/15-LOX führt, wie
folgt beschrieben werden: IL-4 induziert über die Aktivierung von JAK-Kinasen eine
Phosphorylierung von STAT6, dessen Bindung an den 12/15-LOX Promotor jedoch
zunächst durch nicht-acetylierte Histonproteine verhindert wird. Nach 9-11 Stunden
werden Histone und der phosphorylierte STAT6 durch die Acetyltransferase-Aktivität
von CBP/p300 acetyliert. Diese Reaktion führt zu einer Veränderung der Histonstruktur,
wodurch die Bindung von modifizierten STAT6 und damit die Expression des 12/15-
LOX Gens ermöglicht wird.
Als wesentliche zellphysiologische Konsequenz der IL-4 induzierten 12/15-LOX
Expression in A549 Zellen, wurde eine Apoptoseinduktion beobachtet. Das endogene
12/15-LOX Produkt 15-HETE bindet an den Kernrezeptor PPARg und induziert damit
den programmierten Zelltod. Vorinkubation von A549 Zellen mit dem LOX-Hemmstoff
NDGA oder der Einsatz von PPARg Dominant Negativ Vektor verhinderten die
Apoptose. Mechanistische Untersuchungen zum Ablauf des durch IL-4 induzierten
Zelltodes zeigten, dass der Prozess überwiegend dem extrinsischen Mechanismus folgt,
bei dem Kaspasen-8 direkt zu einer Aktivierung der Effektorkaspase-3 führt. Der
mitochondriale Mechanismus (Spaltung von Bid bzw. initiale Cytochrom C Freisetzung)
scheint dabei nicht involviert zu sein. Die IL-4 induzierte Apoptose könnte von patho-
physiologischer Bedeutung für den Verlauf von Lungenerkrankungen sein, bei denen
Zellen mit hoher konstitutiver 12/15-LOX Expression, z.B. eosinophile Granulozyten,
beteiligt sind.
Hepoxiline sind bioaktive Mediatoren des 12/15-LOX Weges der
Arachidonsäurekaskade, die durch Isomerisierung des primären Oxygenierungsproduktes
12S-HpETE gebildet werden. Zu Beginn unserer Untersuchungen war überwiegend
unklar, welche Enzyme an der Isomerisierungsreaktion beteiligt sind. Bei der Suche nach
geeigneten zellulären Modellen für die Untersuchung dieser Fragestellung fanden wir
heraus, dass in den Ratteninsulinom-Zellen Rinm5F, die wegen ihres Mangels an
Glutathionperoxidasen eine geringe Kapazität zur Reduktion von 12S-HpETE aufweisen,
die Synthese von Hepoxilin A3 (HXA3) besonders hoch ist. Da wir vermuteten, dass
12/15-LOXs für die Isomerisierung von 12S-HpETE zu HXA3 verantwortlich sein
könnten, verfolgten wir eine duale Forschungsstrategie um experimentelle Hinweise für
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unsere Arbeitshypothese zu finden. In den 12/15-LOX exprimierenden Rinm5F Zellen
führte eine Immunopräzipitation mit 12/15-LOX spezifischen Antikörper zu einen
vollständigen Verlust der 12/15-LOX- und der Hepoxilinsynthase-Aktivität eines
Zelllysates. Beide Aktivitäten wurden fast vollständig im Immunopräzipitat
wiedergefunden. 2. Transfektion von HeLa Zellen, die selbst keine 12/15-LOX
exprimieren, mit 12/15-LOX und gleichzeitige Hemmung der zellulären
Glutathionperoxidasen (Depletion von GSH mit Diethlmaleat) führte zu einer deutlichen
zellulären Hepoxilinsynthese. Bei entsprechenden Kontrolltransfektanten wurde diese
Aktivität nicht beobachtet. Weiterhin konnte festgestellt werden, dass rekombinante
12/15-LOXs (Expression in E. coli) in vitro eine intrinsische Hepoxinsynthase-Aktivität
aufweisen, wenn 12S-HpETE als Substrat angeboten wird. Diese Daten belegen, dass
12/15-LOXs neben den bisher beschriebenen katalytischen Aktivitäten (Oxygenase,
Hydroperoxidase, Leukotrienesynthase) auch Hepoxilinsynthase-Aktivität aufweisen.
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ABSTRACT
12/15-Lipoxygenases (human 15-LOX-1, rat 12/15-lipoxygenase) belong to family of
lipid peroxidising enzymes. The enzyme has been implicated with roles in a variety of
pathological conditions such as asthma, atherosclerosis, inflammation and in cellular
differentiation. The enzyme expression in most human cell types is tightly regulated by
Th2 cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13). Interleukin-4 (IL-4)
induces expression of reticulocyte-type 15-lipoxygenase-1 (15-LOX-1) in various
mammalian cells via the Janus kinase/signal transducer and activator of transcription 6
(STAT6) signaling system. 15-LOX-1 mRNA expression was first observed only 12h
post IL-4 stimuation and required a minimum of 11h exposure to the cytokine. The
mechanism of 15-LOX-1 induction in A549 lung epithelial cells and the observed delay
was studied and it was found that genistein, a potent tyrosine kinase inhibitor, prevented
phopsphorylation of STAT6, its binding to the 15-LOX-1 promoter, and the expression of
catalytically active enzyme. In contrast, cycloheximide did not prevent 15-LOX-1
induction. Surprisingly, it was observed that IL-4 up-regulated the histone
acetyltransferase activity of CREB-binding protein (CBP)/p300, which is responsible for
acetylation of nuclear histones and STAT6. The acetylation of both proteins appears to be
essential for the IL-4-induced signal transduction cascade, because inhibition of
CBP/p300 by the viral wild-type E1A oncoprotein abrogated acetylation of both histones
and STAT6 and strongly suppressed transcriptional activation of the 15-LOX-1 gene.
Moreover, the inhibition by sodium butyrate of histone deacetylases, which apparently
suppress 15-LOX-1 gene transcription, synergistically enhanced the IL-4-stimulated 15-
LOX-1 expression. These data suggest that both phosphorylation and acetylation of
STAT6 as well as acetylation of nuclear histones are involved in transcriptional activation
of the 15-LOX-1 gene, although these reactions follow differential kinetics. STAT6
phosphorylation proceeds within the first hour of IL-4 stimulation. In contrast,
CBP/p300-mediated acetylation requires 9-11 h, and similar kinetics were observed for
the expression of the active enzyme. Thus, the results suggest that in the absence of IL-4,
nuclear histones may be bound to regulatory elements of the 15-LOX-1 gene, preventing
its transcription. IL-4 stimulation causes rapid phosphorylation of STAT6, but its binding
to the promoter appears to be prevented by nonacetylated histones. After 9-11 h, when
vhistones become acetylated, STAT6 binding sites may be demasked so that the
phosphorylated and acetylated transcription factor can bind to activate gene transcription.
The proinflammatory cytokine IL-4 is secreted in large amounts during allergic
inflammatory response in asthma and plays a pivotal role in the airway inflammation. IL-
4 has been shown to up-regulate 15-lipoxygenase and produce 15(S)-
hydroxyeicosatetraenoic acid (15(S)-HETE) in A549 cells via the Janus kinase/STAT6
pathway under coactivation of CREB binding protein/p300. IL-4 has also been shown to
up-regulate peroxisome proliferator-activated receptor (PPARg ) nuclear receptors in
macrophages and A549 cells. In this study it is observed that 15(S)-HETE binds to
PPARg  nuclear receptors and induces apoptosis in A549 cells. Moreover, pre-treatment
of cells with nordihydroguaiaretic acid, a 15-lipoxygenase inhibitor, prevented PPARg 
activation and apoptosis. The latter was accomplished by the interaction of the 15(S)-
HETE/PPARg  complex with the adapter protein Fas-associating protein with death
domain and caspase-8, as shown by transfection of Fas-associating protein with death
domain dominant negative vector and cleavage of caspase 8 to active subunits p41/42 and
p18. Whereas IL-4 and PPARg  ligands failed to induce cleavage of Bid and release of
cytochrome c from mitochondria, they caused translocation of the proapoptotic protein
Bax from cytoplasm to mitochondria with a concomitant decrease in the Bcl-XL level.
The cells were, thereofre, observed to follow the extrinsic pathway of apoptosis where
caspase-8 directly activates the effector caspase-3, bypassing the mitochondria. The data
also suggests that in IL-4-stimulated cells the 15(S)-HETE/PPARg complex down-
regulates Bcl-XL, and the translocation of Bax to the mitochondria commits the cell
 to
apoptosis. The IL-4-induced apoptosis may contribute to severe loss of alveolar structures
and infiltration of eosinophils, mononuclear phagocytes, etc., into the lung tissue as
observed in chronic asthma patients.
The 12(S)-lipoxygenase (12-LOX) pathway of arachidonic acid (AA) metabolism after
dioxygenation to 12(S)-hydroperoxy-eicosatetraenoic acid is bifurcated in a reduction
route to formation of 12(S)-hydroxy-eicosatetraenoic acid (12-HpETE) and an
isomerization route to formation of hepoxilins. Interestingly, rat insulinoma RINm5F
cells, which are devoid of cytoplasmic glutathione peroxidase (cGPx)/phospholipid
hydroperoxide glutathione peroxidase (PHGPx), were observed to produce solely
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hepoxilin A3 (HXA3). Since HXA3 synthesis was abolished in heat-denatured or cGPx- or
PHGPx-transfected cells, suggesting that a HXA3 synthase activity regulated by
cGPx/PHGPx is present. To confirm this assumption AA was incubated with HeLa cells
overexpressing the rat 12/15-LOX. Neither HXA3 nor 12(S)-HETE were detected due to
abundance of cGPx/PHGPx. But, pretreatment of transfected cells with diethyl maleate,
an inhibitor of glutathione and PHGPx, restored HXA3 synthase and 12-LOX activities.
Moreover, recombinant rat 12/15-LOX produced HXA3 when incubated with 12-
HpETE. Further confirmation was obtained by immunoprecipitation with 12/15-LOX
specific antibodies. Immunoprecipitation of Rinm5F lysates results in the depletion of
hepoxilin synthase activity. The hepoxilin synthase activity was localised in the
immunoprecipitated protein. Thus, cells containing rat 12/15-LOX also possess an
intrinsic HXA3 synthase activity, which is activated by inhibition of cGPx/PHGPx. In
normal cells HXA3 is down-regulated by cGPx/PHGPx, but, it is persistently activated in
oxidatively stressed cells deficient in cGPx/PHGPx, such as Rinm5F. Furthermore,
formation of corresponding epoxyhydroxy products was observed when 15-HpETE was
used as substrate, indicating a broad range of specificity for the enzyme.
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1. INTRODUCTION 
1.1 Lipoxygenases as lipid peroxiding enzymes. 
Lipoxygenases form a family of non-heme iron containing enzymes, which dioxygenate 
polyunsaturated fatty acids at specific postions to produce a series of hydroperoxy fatty acids. 
A variety of substrates such as free fatty acids, membrane phospholipids and lipoproteins can 
be used as substrates for peroxidation by the lipoxygenases. These enzymes specifically 
recognise the 1-cis, 4-cis pentadiene structures to introduce molecular dioxygen and create a 
cis-trans conjugated diene. The most accepted hypothesis for the lipoxygenase reaction is the 
radical hypothesis (Kühn et al., 1986b;  Kühn and Thiele, 1999) according to which the 
reaction consists of three major steps (figure 1): 
a) hydrogen is abstracted from the bisallylic methylene. The specificity of the hydrogen 
abstraction, both positional- and stereo-selectivity (-S, -R), depends upon the orientation of 
the substrate at the active site and by the specificity properties of the enzyme.  
b) re-arrangement of the radicals leading to the formation of a cis-trans conjugated diene 
system. The direction of the rearrangement ([-2] or [+2]) is determined again by the 
orientation in the active site. 
c) the molecular dioxygen is inserted sterospecifically forming a peroxy radical, which is 
subsequently reduced to hydroperoxide anion.   
 
H        H H       H
H3C-R R‘-COOH 
hydrogen abstraction 
 
R‘-COOH. 
      H  H       H
H3C-R  
radical rearrangement
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Radical mechanism of the lipoxygenase reaction 
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1.2 Diversity of the lipoxygenase family 
This family of enzymes is widely distributed in the animal and plant kingdom (Kühn and 
Thiele, 1999; Brash, 1999, Mack et al., 1987; Grechkin, 1998). Lipoxygenases have also been 
discovered in lower organisms, such as corals (Brash et al., 1996), fungi (Bisakowski et al., 
1997; Su and Oliw, 1998) and even bacteria (Porta and Rocha-Sosa, 2001). The nomenclature 
of the enzyme is based upon the number of the carbon atom which is preferentially 
oxygenated in arachidonic acid (AA). The positional nomenclature is further specified by 
mentioning the tissue source of the lipoxygenase e.g. leukocyte, platelet, and the 
stereospecificty by adding S and R to the name. This system is, however, fraught with 
difficulties. The 12-lipoxygenases of leukocyte type share only 40% homology with the 12-
lipoxygenase of platelet type. On the other hand they are 75% similar to 15-lipoxygenase of 
the reticulocyte type (Yamamoto, 1992). Phylogenetic classification (Kühn and Thiele, 1999) 
of the various mammalian lipoxygenases leads to the subdivision of these enzymes into 4 
main subtypes (figure 2): 12/15 lipoxygenases, 5 lipoxygenases, 12 lipoxygenase of the 
platelet type and the epidermis type lipoxygenases. This has been proven to be a more rational 
system since enzymes with similar sequence, structure and activity are grouped together like 
15-LOX and 12-LOX leukocyte type. 
 
mouse epidernmal 12(S)-LOX 
X
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2. Phyloge
 
 human reticulocyte-type 15(S)-LO
porcine leukocyte-type 12(S)-LOX12/15S-LOXsbovine leukocyte-type 12(S)-LOX 
rabbit leukocyte-type 12(S)-LOX 
rabbit reticulocyte-type 12(S)-LOXplatelet-type 
12S-LOXs 
rat leukocyte-type 12(S)-LOX 
mouse leukocyte-type 12(S)-LOX human platelet-type 12(S)-LOX
mouse platelet-type 12(S)-LOXmouse 5(S)-LOX
rat 5(S)-LOX5S-LOXshamster 5(S)-LOX
human 5(S)-LOX 
human epidermis-type 12(R)-LOX 
epidermis-type 
LOXs 
mouse epidermis-type 12(R)-LOX human epidermis-type 15(S)-LOXmammalian 
LOXsmouse epidermis-type 8(S)-LOX 
netic tree of mammalian lipoxygenases. 
Introduction  3
 
 
1.3 12/15 lipoxygenases: Protein chemical and enzymatic properties 
So far the 12/15-lipoxygenase (12/15-LOX) family consists of murine, rat, bovine and porcine 
leukocyte 12-lipoxygenases, rabbit reticulocyte 15-lipoxygenase (15-LOX) and human 15-
lipoxygenase-1 (15-LOX-1). These enzymes share a remarkable degree of homology with 
each other both at the protein, and DNA level. They also exhibit many common enzymatic 
properties such as broad range of substrate specificity and reaction kinetics (Yamamoto, 
1992). To date, the simultaneous expression of these enzymes in the same species has been 
observed only in rabbits (Berger et al., 1998) leading to the hypothesis that leukocyte type 12-
LOX in other species may be functionally complementary to the 15-LOXs in rabbits and 
humans.  
A 15-LOX was first observed in rabbit reticulocytes where it was shown to play an important 
role in the maturation of reticulocytes to erythrocytes (Schewe et al., 1975; Rapoport et al., 
1979). Later, this enzyme was also described in human eosinophils (Sigal et al., 1988) and 
bronchial epithelial cells (Henke et al., 1988; Nadel et al., 1991). The enzyme consists of 663 
amino acids, 75 kDa, and the degree of similarity between the two species is more than 99%. 
In pigs, it was first purified from leukocytes (Yoshimoto et al., 1982), in mice from spleen 
(Chen et al., 1994) and in rat brain (Watanabe et al., 1993). The murine and porcine enzymes 
share a high degree (about 75%) of sequence homology with rabbit and human 15-LOXs. 
12/15-LOX enzymes exhibit a broad substrate specificity. In contrast to other lipoxygenases, 
they are capable of oxygenating free polyunsaturated fatty acids like arachidonic acid (AA), 
linoleic acid (LA) and linolenic acids, esterified lipids like mono, di and tri-acylglycerols, 
cholesterol esters and phospholipids as well as complex substrates like biomembranes and 
lipoproteins (Rapoport et al., 1979; Schewe et al., 1986). These enzymes exhibit dual 
positional specificity with arachidonic acid. The ratio of 12- to 15-HETE varies between the 
lipoxygenases from different species (Yoshimoto and Yamamoto, 1995). The reaction 
proceeds by the abstraction of a hydrogen from the bisallylic methylene  at the C-10 position 
(12-LOX) or at the C-13 (15-LOX) followed by insertion of oxygen. Both the processes occur 
antarafacially i.e. from different sides of the plane of the double bonds.  
 
1.3.1 Tissue distribution 
The tissue distribution of 12/15-LOXs varies in different species. In rat, the 12-leukocyte type 
enzyme is maximally expressed in the pineal gland followed by leukocytes, macrophages, 
lung, spleen, pituitary, pancreatic beta cells and aorta, while in mouse, the maximum 
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expression was seen in the peritoneal macrophages, kidney and pineal gland with weaker 
signal observed in intestine, spleen and aorta (Yoshimoto and Takahashi, 2002). Simultaneous 
expression of both 12(S) leukocyte type and 15-LOX was observed in rabbits (Berger et al., 
1998). The 12-leukocyte type enzyme was detected in the tracheal epithelium and leukocytes 
of cows and in the pitutary gland and leukocytes of pigs. 15-LOX-1 is the only 12/15-LOX 
isoform which has been detected in humans. It is expressed constitutively in bronchial 
epithelium and eosinophils (Sigal et al., 1988) though expression is also observed in 
monocytes and colonic epithelium upon cytokine (IL-4) stimulation.  
 
1.3.2 Suicide inactivation 
Another interesting feature of this enzyme is the property of suicide inactivation. Reaction 
with fatty acids rapidly slows down and stops within several minutes of incubation (Rapoport 
et al., 1984; Hada et al., 1991). This is due to a complex set of mechanisms not yet clearly 
understood. Kishimoto et al., 1996, have shown that 15(S)-HpETE produced as product of 
AA metabolism covalently binds to the 12-LOX leukocyte protein and inactivates the 
enzyme. This feature has also been observed from the rabbit 15-LOX. Epoxide products of 
15-HpETE, such as 14,15-LTA4 involve the formation of radical intermediates, which were 
hypothesised to covalently link to active site residues causing enzyme inactivation. Inhibition 
was also observed with LA independent of covalent linkages suggesting the proposed LTA4 
mechanism may not be exclusive (Wiesner et al., 2003).  
 
1.3.3 Structural requirements for 12/15 lipoxygenation 
Among the mammalian lipoxygenases, the X-ray crystal structure is available only for the 
rabbit 15-LOX (Sloane et al., 1990; Gillmor et al., 1997). Much of the information about 
structure and function of this protein has been elucidated utilising the crystal structure data 
along with site-directed mutagenesis and modified substrates. The enzyme is composed of a 
large C- terminal catalytic domain containing the non-heme iron and a small N-terminal beta 
barrel domain. The substrate binding site is a large boot shaped hydrophobic cavity, which 
contains the non-heme iron catalytic centre (Gillmor et al., 1997). The active site is lined 
mainly by the hydrophobic side chains of amino acids.  Phe 353, Ile 418, Met 419, Ile 593 
form the bottom of substrate binding cavity and a positively charged Arg 403 is positioned at 
the entrance of the active site. It has been proposed that the substrate fatty acid slide into the 
active site with its methyl end ahead and the positively charged Arg 403 interacts with the 
carboxy group forming a salt bridge (Gan et al., 1996). Replacement of this residue with a 
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neutral amino acid residue severely impaired the dioxygenation process. Inside the active site 
the methyl end interacts with various side chains to position the bisallylic methylene C-13 of 
the substrate close to the iron atom for hydrogen abstraction. Site-directed mutagenesis 
studies have revealed that Phe 353 (Borngräber et al., 1996), Ile 418, Met 419 and Ile 593 
(Sloane et al., 1991; Borngräber et al., 1999) are the positional determinants of 15 
lipoxygenation (C-13 abstraction) single or combined. Mutation to these amino acids to 
residues with less bulkier side chains (alanine) converted the enzyme to a 12-LOX. The 
overall cavity size of 12-LOX leukocyte type was predicted to be moderately bigger, allowing 
the substrate to slide in deeper and aligning the C-10 of AA atom for hydrogen abstraction at 
the non-heme iron. 
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substrates and site directed mutagenesis (Schwarz et al., 1998; Walther et al., 2001). Thus, the 
determinant of positional specificity is not only the volume but also the orientation of the 
substrate in the active site.  
The N-terminal domain of the enzyme does not play a major role in the dioxygenation 
reaction of 12/15 lipoxygenase. N-terminal domain truncations did not impair the 
lipoxygenase activity. The  ability of the enzyme to bind to membranes, however, is impaired 
in the mutants (point and truncations) of the N-ternimal domain without significant alterations 
to the catalytic activity (Walther et al., 2002). Mutation to Trp 181, which is localised in the 
catalytic domain, also impaired membrane binding function. This suggests that the C-terminal 
domain is responsible for the catalytic activity and a concerted action of N-terminal and C-
terminal domain was necessary for effective membrane binding. 
 
1.4 Regulation of 12/15-LOX expression 
The expression of 15-LOX can be controlled at the transcriptional, translational, post-
translational levels (Kühn et al., 1999, Kühn et al., 2002). 
1.4.1 Transcriptional regulation 
1.4.1.1 Rabbit 15-LOX: Constitutive expression of rabbit 15-LOX is observed only in 
reticulocytes under the condition of experimental anemia, where it is strongly expressed in 
peripheral monocytes, lung, liver, spleen and kidneys (Schewe et al., 1975; Rapoport et al., 
1979). The mechanism of induction of 15-LOX during experimental anemia is still unclear. 
O’Prey and Harrison, 1995, studied the promoter region of the gene and found a number of 
negative and positive regulatory elements, which are differentially regulated in erythroid (15-
LOX expressing)  and non-erythroid cell lineages (non-expressing). In 1 Kb of 5’ region 
flanking the 15-LOX gene, they observed multiple copies of a putative transcriptional silencer 
element, which function only in non-erythroid cell lineages. DNAse I mapping studies 
revealed protein binding to these elements only in non-erythroid cells and not in erythroid 
cells. This element was therefore suggested to function like a silencer element in non-
erythroid cells, inhibiting the transcription of the gene. Several other positive regulatory 
elements were observed in erythroid cells, which could putatively bind to transcription factors 
such as GATA proteins.  
1.4.1.2 Human 15-LOX-1: In humans, the Th2 cytokines, IL-4 and IL-13 have been shown 
to upregulate the expression of this gene in peripheral monocytes (Conrad et al., 1992), A549 
lung epithelial carcinoma cells (Brinckmann et al., 1996), human tracheobroncheal cells 
(Jayawickreme et al., 1999), endothelial cells (Lee et al., 2001) and in Caco-2 colon 
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carcinoma cells (Kamitani et al., 2000). Human alveolar macrophages appear to constitutively 
express 15-LOX-1 in low levels as indicated by activity assays (Levy et al., 1993). Other 
cytokines did not induce the enzyme. In fact, the Th1 cytokine IFNγ was observed to inhibit 
gene expression induced by IL-13 in monocytes (Nassar et al., 1994). The IL-4 and IL-13 
pathway share JAK1/2 kinases and transcription factor STAT6 (Heim, 1999). IL-4 and IL-13 
failed to elicit any response in monocytes prepared from STAT6 deficient mice (Heydeck et 
al., 1998) and in human monocytes antisense treatment showed the involvement of JAK2 and 
TYK2 kinases in the upregulation (Roy and Cathcart, 1998). Pretreatment of the cells with 
IFNγ inhibited the phosphorylation of these kinases and stopped the signal transduction 
cascade. Involvement of factors such as SOCS (suppressors of cytokine signalling) have 
implicated in this process (Dickensheets et al., 1999).  
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1997). Several other prominent transcription factor binding sites have been identified in this 
promoter region. A single copy of the  “silencer element” identified in rabbit 15-LOX is 
present in the human promoter, however its function has not been elucidated. Kevalkar et al., 
1998, have identified a 29 bp region (-352 to -304) which is important for the cytokine 
induced expression. Deletion of this region resulted in the absence of expression. Ku 70/80 
has been identified as the protein binding to this region and controlling the gene expression 
(Kelavkar et al., 2000b). In Caco-2 cells, histone acetylation has been shown to play an 
important role. Cells treated with sodium butyrate, a hisone deacetylase inhibitor, expressed 
15-LOX-1 without cytokine stimulation (Kamitani et al., 2001). Histone remodelling is a well 
known regulator of gene transcription and adds an interesting dimension to the study of 
transcription regulation of 15-LOX-1. 
1.4.1.3 Leucocyte type 12-LOX: Expression of 12/15-LOX was induced in porcine smooth 
muscle cells (Natarajan et al., 1996) and murine system by IL-4 and IL-13 (Conrad et al., 
1992), however, the involvement of STAT6 is not clear. No induction of 12/15-LOX 
expression by IL-4 was observed in peritoneal macrophages from STAT6 deficient mice 
(Heydeck et al., 1998) but the constitutive expression of the enzyme was not affected 
(Sendorby et al., 1998). Another cytokine IL-1β has been observed to upregulate rat 12/15-
LOX expression in rat insulinoma cells both at the mRNA and protein levels (Bleich et al., 
1995). Other authors have suggested that IL-1β induced expression of 12/15-LOX depends on 
an increased availability of substrate and on the cellular nitric oxide levels (Ma et al., 1996). 
Melatonin, a hormone involved in seasonal control of metabolism, significantly 
downregulated 12/15-LOX activity in pineal gland. It has been suggested that melatonin acts 
as an endogenous modulator of the 12 Lipoxygenase protein (Zhang et al., 1999). Though, a 
number of molecules appear to modulate the activity and expression of 12/15-LOX, the 
mechanisms or the signal transduction pathways responsible have not been elucidated in 
detail.  
 
1.4.2 Translational regulation: 
Translational regulation of 12/15 lipoxygenase expression has been investigated in detail in 
rabbit reticulocytes (Thiele et al., 1982), where it plays a major role in the maturation of the 
cell to erythrocyte. Abundant quantities of 15-LOX mRNA is present in immature rabbit 
reticulocyte but no active LOX enzyme could be detected. During maturation, the protein is 
expressed which by acting specifically on the mitochondrial membranes and promotes 
organelle degradation (Schewe et al., 1975). This process is controlled by translational 
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silencing by hnRNP k and E1 (Ostareck et al., 1997). These two RNA binding proteins bind 
to specific elements known as DICE (differentiation control elements) present in the 
3’untranslated region of the 15-LOX mRNA . These elements consists of poly UAA stretches 
repeated several times. In cell free system, the hnRNP proteins specifically inhibit the 
assembly of 80S ribosome on the 15-LOX mRNA, thus preventing translation (Ostareck et 
al., 2001). As the process of maturation proceeds, the two proteins detach from the mRNA, 
thus permitting the translation to proceed.  
 
1.4.3 Post-translational regulation: 
1.4.3.1 Hydroperoxide tone: A major factor in the regulation of the 12/15 LOX activity is 
the hydroperoxide tone, which quantifies the sum of all hydroperxides present in the cell 
(Weitzel and Wendel, 1993). Hydroperoxides activate LOXs by converting the non-heme iron 
from the ferrous to a ferric form. Inhibition of this conversion, by specific inhibitor like OPP, 
prevents the catalytic action of these enzymes (Richards et al., 1999). In vivo the 
hydroperoxide tone in the cell is regulated by glutathione dependent peroxidases. These 
enzymes convert hydroperoxy fatty acid to the hydroxide form, and this is paralleled by 
oxidation of GSH to GSSG (Hurst et al., 2001).  
1.4.3.1.1 Selenoenzymes: The Glutathione peroxidase (GPx) family consists of 4 major 
subfamilies: i) classical intracellular glutathione peroxidase (GPx-1), ii) plasma GPx, iii) 
gastro-intestinal Gpx (GI-GPx) and iv) phospholipid hydroperoxide GPx (PHGPx) (Flóhe et 
al., 1973; Takahashi et al., 1987; Chu et al., 1993). The common structural feature of these 
enzymes is presence of a selenocysteine residue. Of these, GPx-1 and PHGPx are the best 
characterised isoforms and they are found in almost all cell types. GPx-1 is a 26 kDa cytosolic 
protein, which exists as a homotetramer and utilises intracellular free hydroperoxy fatty acids 
as substrates (Flóhe, 1989). PHGPx, on the other hand, is a 23 kDa protein, which exists as a 
monomer and has the ability to react not only with free hydroperoxy fatty acids but also with 
esterified hydroperoxy fatty acids. It is preferentially associated with the membranes (Ursini 
et al., 1985; Thomas et al., 1990; Roveri et al., 1994).  
These enzymes constitute an important part of the cellular anti-oxidant defence system. 
Overexpression of PHGPx has been observed to reduce apoptosis caused by oxidative stress 
in rat basophilic leukemia cells (Imai et al., 1996). The mitochondrial form of the enzyme has 
been found to be particularly effective as indicated by inhibition of apoptosis and increase in 
the level of Bcl-2, a mitochondrial anti-apoptotic protein (Nomura et al., 1999). 12/15-LOX 
can utilise membrane phospholipids as substrates for oxygenation. Pre-incubation of 
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membranes with PHGPx inhibited the oxygenation reaction, which was reversed by the 
addition of hydroperoxides (Schnurr et al., 1996). IL-4 and IL-13 treatment of A549 cells 
causes induction of 15-LOX-1 but also a concomitant decrease in the levels of PHGPx 
(Schnurr et al., 1999). Analysis of various tissues of mice overexpressing IL-4 revealed a 
negative correlation between the PHGPx levels and increased arachidonic acid oxygenase 
activity in certain tissues. This observation suggests that lipid peroxide generating and 
reducing enzymes are inversely regulated in various mammalian cells. It has been reported, 
that PHGPx is primarily responsible for the regulation of 5-lipoxygenase activity in rat 
leukocyte (Weitzel and Wendel, 1993).  
A major reduction in the glutathione peroxidase activity was observed in the platelets from 
selenium deficient rats (Bryant et al., 1980). These platelets produced at least seven fold 
higher amounts of 12-HpETE as compared to control rats ((Bryant et al., 1983). Similar 
results were obtained in leukocytes from selenium deficient rats (Ho et al., 1997). Moreover, 
the selenium deficient rat platelets showed a three fold increase in the synthesis of isomeric 
trihydroxy fatty acids, TrXA3 and TrXB3 (Bryant et al., 1983). The isomerization pathway 
produces HXA3 and HXB3 from 12 HpETE which are rapidly hydrolysed by epoxide 
hydrolases to TrXA3 (Pace-Asciak and Lee, 1989). As the reductase activity of glutathione 
peroxidase is limited in selenium deficient rat platelets, the metabolism of 12-HpETE is 
diverted towards the isomerization route. This suggests the importance of glutathione 
peroxidases in the reduction of 12-HpETE. These authors, however, assume  that  the 
classical glutathione peroxidase, GPx-1 is the sole selenium dependent glutathione peroxidase 
enzyme present in platelets. However, platelets from GPx-1 knockout mice incubated with 25 
µM arachidonic acid still synthesised 12-HETE (Ho et al., 1997). Furthermore, Gpx-1 
deficient mice exhibited no phenotypic changes and the rate of lipid peroxidation and 
consumption of exogenous H2O2 was not altered in the tissues when compared with normal 
mice. This implies the ability of other enzyme(s) to take over the function of GPx-1, namely 
PHGPx. Selenium depletion studies also revealed a different response pattern between GPx-1 
and PHGPx (Bermano et al., 1995). Severe selenium deficiency in rats caused complete loss 
of GPx-1 activity and GPx-1 mRNA levels in liver and heart, while the PHGPx activity was 
reduced by only 75%, and the mRNA levels were unaffected. In selenium-deficient rat 
basophilic leukemia cells, <1% GPx activity and 35% PHGPx activity were observed as 
compared to control cells and upon activation an enhanced 12-lipoxygenase activity was 
observed. Replenishment of selenium to these cells restored the PHGPx activity within 8 h, 
while the GPx-1 activity needed 7 days to return to normal levels (Weitzel and Wendel, 
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1993). The role of PHGPx and GPx-1 in the regulation of hydroperoxide tone seems to be 
different. An important factor for consideration is the localisation of the enzymes. PHGPx is 
preferentially associated with the membranes, which is also the site of eicosanoid synthesis. 
Similar observation has been reported in human platelets where PHGPx may have a special 
function in the regulation of 12-LOX activity (Sutherland et al., 2001).  
1.4.3.1.2 Selenium independent systems: Using a sensitive HPLC assay, glutathione 
transferases (GST) from α, µ and θ groups were observed to reduce phospholipid 
hydroperoxides to corresponding hydroxides using GSH as the reducing agent (Hurst et al., 
1997). The α group exhibited the maximum activity, though it was significantly lesser than 
that of PHGPx. Also, in contrast to the glutathione peroxidases, these enzymes were inactive 
in the presence of detergent, Triton X100 (Hurst et al., 1998). The π enzymes were, however, 
inacapable of reducing phospholipid hydroperoxides. Although, the activity of the GSTs is 
significantly lower than that of the glutathione peroxidases, their relative abundance (nearly 
5% of total cellular protein) could be important. The activity of this class of enzymes with 
free fatty acid hydroperoxide, however, has not been reported so far. 
Recently, a novel non-selenium glutathione peroxidase has been identified. The enzyme, 1-
Cys peroxiredoxin, was first isolated from the bovine ciliary body in the olifactory mucosa 
(Shichi and Demar, 1990) and has been shown to catalyze the reduction of both free fatty acid 
hydroperoxides and phospholipid hydroperoxides using glutathione as electron donor (Fisher 
et al., 1999). This enzyme had no glutathione transferase activity when assayed with a 
spectrum of potential SH donors (Shichi and Demar, 1990). Furthermore, 1-Cys 
peroxiredoxin also exhibited PLA2 like activity and both the activities were reported to reside 
in distinctive active sites (Chen et al., 2000).  
 
1.4.3.2 Other factors: Nitric oxide has been shown to regulate the activity of 12/15-LOXs in 
vitro. Short incubations of the enzyme with NO considerably increases the kinetic lag phase 
which was shortened upon long term incubations (Holzhütter et al., 1997). Together with EPR 
and X-ray absorption studies, these data suggest that during NO-LOX interaction oxidation of 
ferrous non-heme iron may have occurred (Wiesner et al., 1996).  
 
1.4.3.3 Regulation by calcium: 12/15-LOXs exhibit the capability to oxidise biomembranes. 
In vitro reticulocyte-type 15-LOX was observed to bind reversibly to biomembranes such as, 
submitochondrial particles and erythrocyte ghosts (Brinckmann et al., 1998). This membrane 
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binding activity was enhanced by the addition of calcium. Interestingly, the addition of 
calcium also enhanced the membrane oxygenase activity of the enzyme. This feature was 
confirmed in vivo. In rabbit reticulocytes and IL-4 stimulate peripheral monocytes, electron 
microscopic studies showed the localisation of the enzyme to the plasma and intracellular 
vesicles. Calcium ionophore augmented the membrane binding share of 15-LOX in human 
eosinophils, where it is expressed constitutively. Only under these conditions were specific 
lipoxygenase products of membrane lipids observed membrane oxygenase activity observed 
(Brinckmann et al., 1998). Thus, calcium not only enhances the membrane translocation but 
also the catalytic activity of 15-LOX in hematopoetic cells. Similar observations were made 
in colon carcinoma, Caco-2, cells. The presence of calcium was essential for the translocation 
and the catalytic activity of the 15-LOX-1, which was overexpressed in these cells (Hsi et al., 
2001). 
  
1.5 Metabolites of 12/15-LOX pathway 
The predominant product of AA and LA (the major polyunsaturated fatty acids in mammalian 
cells) metabolism is 12-HpETE, 15-HpETE and 13-HpODE. These metabolites can be further 
processed into 3 primary types of products. 
 
1.5.1 Peroxide reduction pathway: 12-HpETE, 15-HpETE and 13-HpODE can be converted 
to the corresponding hydroxides by the action of glutathione peroxidases.  
1.5.2 Double and triple oxygenation pathway (Oxygenase activity): Lipoxin B4 
(5S,14R,15S-trihydroxy-6E,8Z,10E,12E-eicosatetraenoic acid) is a product of the 15 
lipoxygenase (Kühn et al., 1987). Lipoxin B4 is a biologically important compound. It is 
involved in the activation of leukocytes and the inhibition of neutrophil recruitment, 
chemotaxis and adhesion (Fierro et al., 2002). Lipoxins, especially aspirin triggered 15-epi-
lipoxin A4, are potent inhibitors of acute inflammation (Takano et al., 1997). 
1.5.3 Epoxy-leukotriene pathway (LTA4 synthase activity): A concerted action of the 
oxygenase and hydroperoxidase activty leads to the formation epoxy-leukotrienes such as 
14,15 epoxyleukotriene A4 (Bryant et al., 1985). 
1.5.4 Lipohydroperoxidase pathway (Hepoxilin synthase activity): The hydroperoxy 
group is homolytically cleaved to alkoxy radical initiating the formation of epoxyhydroxy 
compounds (involving the hydroperoxidase activity), keto-dienes, aldehydes and alkanes 
(Veldink et al., 1997). Of these, the epoxyhdroxy compounds of 12-LOX , hepoxilins, have 
been best studied (Pace-Asciak and Asotra, 1989). 
Introduction  13
 
1.5.4.1 Hepoxilins: Hepoxilins are monohydroxy-epoxy derivatives of arachidonic acid 
which are products of 12-HpETE. Two forms of hepoxilin are known, HxA3 (8(R) and 8(S)-
hydroxy-11(S),12(S)-epoxyeicosa-5Z,9E,14Z-trienoic acid and HxB3 (10(R) and 10(S)-
hydroxy-11(S),12(S)-epoxyeicosa-5Z,8Z,14Z-trienoic acid) (Pace-Asciak et al., 1983). The 
intra molecular re-arrangement of 12-HpETE can proceed by two main pathways.  
12(S)-HpETE undergoes heme-dependent isomerization to produce HxA3 and HxB3 in 
equimolar amounts (Pace-Asciak, 1984a; Pace-Asciak and Asotra, 1984; Pace-Asciak, 
1984b). Incubation of a racemic mixture of 12(R/S)-HpETE with hemin produced an 
equimolar mixture of HxA3 and HxB3 and the R derivatives produced the corresponding 
hepoxilins which do not occur in vivo (Pace-Asciak et al., 1995). This reaction was 
insensitive to heat. Both the insensitivity to heat and lack of substrate selectivity suggested 
that hemin catalysed reactions were non-enzymatic. Bryant et al., 1980; 1983, observed that 
platelets from selenium deficient rats produced more 12-HpETE and tri-hydroxy derivatives 
upon incubation with AA. This product was identified as a mixture of isomers of Trioxilin A3 
(TrXA3), hydrolysis product of HxA3.  
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Kinsella, 1986). Rat pineal gland slices, on the other hand incubated with 12(R/S)-HpETE 
produced exclusively HxA3. Here 12(S)-HpETE was selectively consumed (Reynaud et al., 
1994). Tissue, boiled prior to use, did not produce any hepoxilins. Taken together, these data 
indicate the presence of a heat labile enzyme which stereoselectively converts 12(S)-HpETE 
to HxA3. Similar reaction was also observed in rat brain and skin (Pace-Asciak et al., 1993). 
This enzyme, designated as “hepoxilin synthase”, did not seem to require any cofactors.  
Another probable pathway for the production of hepoxilins is the cytochrome P450 pathway. 
Incubation of 15(S)-HpETE with rat liver microsomes produced the mono-hydroxyepoxy 
derivative, 11S-hydroxy-14S,15S-trans-epoxyeicosa-5Z,8Z,12E-trienoic acid (Weiss et al., 
1987). 15(R)-HpETE was converted into the corresponding 15R derivative. The P450 2B1 
enzyme gave products similar to those obtained from the purified microsomes. Similar 
derivatives were also observed upon the incubation of 15-HpETE with garlic root tips 
(Reynaud et al., 1999). Reticulocyte 15LOX, under anaerobic conditions, produces significant 
amounts of a 13-hydroxy-14,15-epoxy eicosatrienoic acid. This compound was also observed 
under aerobic conditions but to a significantly lesser extent (Kühn et al., 1986a). In algae, 
another enzyme has been isolated which produces epoxy hydroxy derivatives from free fatty 
acids (Moghaddam et al., 1990).  
HxA3 is chemically and biologically unstable due to the intrinsic instability of the epoxide 
ring (Pace-Asciak and Lee, 1989; Pace-Asciak and Asotra, 1989). The epoxide ring is rapidly 
hydrolysed in vivo by epoxide hydrolases to form the tri-hydroxy derivative, TrXA3 (8,11,12-
trihydroxy-eicosatrienoic acid) (Pace-Asciak and Lee, 1989; Pace-Asciak et al., 1986). 
Similar reaction also occurs in acidic media, particularly during the acidic extraction of lipids. 
The inhibition of epoxide hydrolase by trichloropropene oxide (TCPO) (Pace-Asciak et al., 
1986) diverts the conversion of HxA3 towards conjugation. Purified Yb2 subunits of 
glutathione transferases produce a glutathione conjugate upon reaction with HxA3 (Laneuville 
et al., 1991). 
 
1.6 Biological role of 12/15 lipoxygenases:  
1.6.1 Cell differentiation 
15-LOX was discovered in rabbit reticulocytes as the agent responsible for the destruction of 
mitochondria during its maturation to erythrocytes. It was hypothesised that peroxidation of 
lipids leads to membrane destruction (Rapoport et al., 1982; Grullich et al., 2001). Recent 
evidence has shown that the enzyme may actually oligomerise and integrate into the lipid 
bilayer leading to the formation of hydrophilic pores (van Leyen et al., 1998). 12/15-LOX 
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deficient mice, however, did not exhibit any significant defects in erythropoiesis (Sun and 
Funk, 1996). These mice did not exhibit any major malfunctions even under conditions of 
experimental anemia. Eye lens cells undergo a similar process of enucleation and destruction 
of organelles during maturation (van Leyen et al., 1998). 15-LOX has been shown to play an 
important role in this process by preferentially targetting the organelle membranes. These 
reports also suggest that similar mechanism might be operative in keratinocytes. A role for 
15-LOX in differentiation of human tracheobronchial cells has also been suggested (Hill et 
al., 1998b). Retinoic acid induced differentiation and the expression of 15-LOX was observed 
in the later stages of the process, while undifferentiated cells do not produce any 15-LOX. 
12/15-LOX translocated to the plasma membrane in monocytes incubated with apoptotic cells 
to the sites where actual contact was observed and altered the actin polymerization suggesting 
a role for this enzyme in the process of phagocytosis (Miller et al., 2001). However, 12/15-
LOX deficient mice did not exhibit any physical abnormalities such as defective eye lens or 
any immune abnormalities. The underlying mechanisms need to be elucidated. 
1.6.2 Bronchial diseases  
Metabolites of arachidonic acid may play a fundamental role as mediators in the development 
of airway inflammation in asthmatics (Chavis et al., 1998). Since the identification of “slow 
reacting substance of anaphylaxis” as leukotrienes C4/D4 most of the research on asthma was 
concentrated around the key enzyme 5-lipoxygenase, which led to development of numerous 
drugs. However, a real breakthrough has not yet been achieved. It is now known that the 
bronchial hyperreactivity is not solely caused by increased release of mediators of 
bronchoconstriction and inflammation, but the increased sensitivity of bronchial receptors 
towards these mediators plays a pivotal role in the pathogenesis of asthma. The lung epithelial 
cells express 5- and 15- lipoxygenases, which produce a variety of metabolites, such as 5-
HETE, 15-HETE and leukotrienes, but also cyclooxygenases (Salari and Chan-Yeung, 1989; 
Hill et al., 1998a). The expression of these enzymes is tightly regulated in different types of 
cells (Moore et al., 2001; Conrad et al., 1992). Expression of 15-LOX enzyme is significantly 
increased in bronchial epithelial cells, and eosinophils (Conrad et al., 1992; Levy et al., 1993; 
Conrad and Lu, 2000). Consequently, large amounts of 15-HETE were observed in bronchial 
epithelial cells of asthmatic and emphysema patients as compared with those of normal 
subjects (Campbell et al., 1993). Since 15-LOX dioxygenates not only free arachidonic acid, 
but also biomembrane phospholipids, a considerable alteration in the affinity of various 
receptors with respect to 15-HETE and other lipid mediators may be expected. IL-4, which is 
also upregulated during asthma promotes incorporation of 15-HETE into the phospholipids 
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(Profita et al., 1999). Similarly exposure of human tracheal epithelial cells to ozone, a major 
oxidant in environmental pollution, increases 15-HETE production and its esterification into 
phospholipids (Alpert and Walenga, 1995). Early allergic response was enhanced upon pre-
inhaling 15-HETE with no effect on the late response (Lai et al., 1990b). Inhaled 15-HETE as 
such did not have differential effects on the airway of either normal or asthmatic individuals 
(Lai et al., 1990a).  
A number of reports have suggested a role for 15-LOX in other bronchial diseases like 
bronchitis and chronic obstructive pulmonary disease (COPD). In COPD patients, alveolar 
apoptosis was observed along with decrease in 15-LOX protein and vascular endothelial 
growth factor RNA levels (Kasahara et al., 2000). Recently, increased 15-LOX-1 protein and 
mRNA expression was observed in the bronchial biopsies from patients suffering from 
chronic bronchitis (Zhu et al., 2002). Further, increased IL-4 protein and mRNA levels were 
also associated with this condition. The association of IL-4 and 15-LOX-1 in bronchial 
diseases is interesting as it has been previously observed that IL-4 strongly upregulated 15-
LOX-1 levels in bronchial cells (Conrad et al., 1992).  
1.6.3 Inflammation 
12/15-lipoxygenase and its metabolites seem to exhibit both pro-inflammatory and anti-
inflammatory activities. Elevated levels of 15-HETE and 13-HODE are associated with 
inflammation in various disorders such as human proctocolitis (Donoiwitz, 1985; Zijlstra et 
al., 1991), psoriasis (Duell et al., 1988). Psoriasis is an interesting example of the complexity 
of the lipoxygenase family. Both 12/15-LOX and 12R-LOX have been identified in psoriatic 
scales from patients (Boeglin et al., 1998). Increased levels of  15(S)-HETE, 12(S)-HETE, 
13(S)-HODE and 12(R)-HETE have been observed in psoriatic cells when compared to 
normal cells (Baer et al., 1991). The relevance of these metabolites in the progression of the 
disease is unclear though pro-inflammatory cytokines such as IL-4 may play an important role 
in this disease (Asadullah et al., 2002). Human rheumatoid arthritis B synoviocytes express 
15-LOX-1 and produce 15-HETE (Liagre et al., 1999). The role of this metabolite has not 
been studied in disease progression even though IL-4 levels were shown to be elevated under 
these conditions. 13-HODE, 12-HETE induced chemotaxis in neutrophils (Henricks et al., 
1991; Cunninghham et al., 1986), however, 15-HETE inhibited the migration of these cells 
across cytokine activated endothelium (Takata et al., 1994a). 
The 12/15-LOX products are capable of exhibiting anti-inflammatory properties in a 
protective role or reverse the inflammatory symptoms. Leukotriene B4, a major 5-LOX 
product is one of the most important mediators of acute inflammation. Remodelling of 
Introduction  17
 
polymorphonuclear leukocyte membranes with 15-HETE reduced the leukotriene B4 cell 
surface receptor affinity (Takata et al., 1994b), similarly increased levels of 15-HETE were 
correlated with inhibition of leukotriene B4 formation and synovial cell proliferation (Herlin 
et al., 1990) in experimental arthritis. Leukotriene B4 synthesis and its chemotactic activity 
were specifically antagonised by 15-HETE in rat experimental glomulonephritis (Fischer et 
al., 1992). Experimental glomerulonephritis was prevented in rat kidneys transfected with 
human 15-LOX-1 gene indicating a major anti-inflammatory role for 12/15-LOX (Munger et 
al., 1999). 15-HETE inhibited superoxide formation and exocytosis in neutrophils stimulated 
with phorbol ester or platelet activating factor (Smith et al., 1993). 
1.6.4 Carcinogenesis 
Many contradictory reports have appeared with respect to the role of 12/15 lipoxygenases in 
carcinogenesis. Transfection of PC3 prostate cancer cell line with 15-LOX-1 showed a pro-
carcinogenic effect as measured by several parameters (Kelavkar et al., 2001). These cells 
exhibited decreased anchorage dependent growth, increased proliferation and an increase in 
levels of angiogenic factors such as vascular endothelial growth factor. The cells also 
produced larger and more tumors when transplanted into athymic nude mice as compared to 
control cells. Prostatectomy specimens showed a significant co-expression of 12/15-LOX and 
mutant p53 coupled with the fact that elevated levels of 13-HODE were found in prostate 
carcinoma samples (Kelavkar et al., 2000a; Spindler et al., 1997). These data also correlated 
with elevated Gleason rating and the level of 12/15-LOX expression. A report which appeared 
six months later, however, showed that 15-LOX-2 metabolite 15-HETE caused dose 
dependent inhibition of PC3 proliferation by activating PPARγ transcription factors (Shappell 
et al., 2001). Recently, Hsi et al., 2002, observed that 13-HODE (15-LOX-1) and 15-HETE 
(15-LOX-2) have opposing effects on the regulation of PPARγ in epidermal growth factor 
signalling in prostate cancer cells and offer this as an explanation to the contradictory results 
obtained. Thrombin produced rapid pseudopod formation and detachment involving the 
formation of 12 and 15-HETE in rat prostatic carcinoma cells (Ross et al., 2000).  
Similar contrasting results were obtained in studies performed on colon carcinoma. Increased 
expression of 12/15-LOX was observed in colon carcinoma tissue as compared to matched 
normal tissue as measured by PCR, protein expression and immunohistochemistry by Ikawa 
et al., 1999. On the other hand, Shureiqi et al., 1999, found significantly reduced amounts of 
immunohistochemical staining and 13-HODE levels in colon carcinoma tissue as compared to 
normal ones. The same group also reported that non-steroidal anti inflammatory drugs 
(NSAIDs) could upregulate 15-LOX-1 and 13-HODE and induce apoptosis in these cells 
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(Shureiqi et al., 2000). Caco-2 colon carcinoma cells exhibited apoptosis upon sodium 
butyrate treatment which corresponded to increased 12/15-LOX expression (Kamitani et al., 
1998, 2001). 
Honn and group have shown in a number of reports that 12-HETE and platelet type 12-LOX 
can function as inducers of carcinogenesis and metastasis (Nie et al., 2001; Honn et al., 
1994a). Furthermore, lipoxygenase inhibitor NDGA induces apoptosis in a number of 
carcinoma cell lines. The role of 12/15 lipoxygenase and its metabolites is complex and the 
mechanism of action of these contradictory effects is yet unclear. 
1.6.5 Atherogenesis  
Atherosclerotic lesions develop in a characteristic fashion, first appearing as fatty streaks. 
They consist of lipid-rich macrophages, foam cells localised beneath an intact endothelial cell 
layer in the arteries (Ross, 1999). Oxidation of LDL plays a key role in the early pathogenic 
events, leading to foam-cell formation and fatty streaks (Witzum, 1994; Steinberg and 
Witzum, 1999). Products of oxidized LDL (oxLDL) are chemotactic for monocytes, promote 
endothelial cell binding of monocytes, and once the monocytes have been recruited, inhibit 
the motility of macrophages. Macrophages can both initiate the oxidation of LDL and take up 
oxLDL in an unregulated manner, leading to foam-cell formation (Steinberg and Witzum, 
1999; Cushing et al., 1990; Watson et al., 1997). There is now considerable evidence to 
support the presence of oxLDL in vivo, at least in animal models (Steinberg and Witzum, 
1999). Many enzyme systems or nonenzymatic oxidative mechanisms have been 
demonstrated to induce oxidation in vitro (Heinecke, 1997). In vitro 15-lipoxygenase has been 
demonstrated to oxidise LDL (Kühn et al., 1994a). 15-LOX transfected fibroblasts and 
monocytic cells exhibited increased conversion to the atherogenic form of LDL (Benz et al., 
1995) and impaired oxidation ability was observed in zymosan treated macrophages from 
12/15-LOX deficient mice (Sun and Funk, 1996). Several other lines of evidence support the 
pro-atherogenic role of 12/15-LOX. The mechanism(s) responsible for oxidation of LDL in 
vivo, however, remain to be defined. Human atherosclerotic lesions showed 12/15-LOX 
activity (Henriksson et al., 1985). Furthermore, 12/15-LOX mRNA and protein have also 
been detected in many different animal models (Hiltunen et al., 1995; Yla-Herttuala et al., 
1990; Hugou et al., 1995), however, due to non-specificity of the experimental procedures 
these results need to be confirmed. The oxLDL from cholesterol fed rabbits showed the 
presence of 12/15-LOX specific products and the presence correlated temporally with the 
onset of lipid deposition on the arterial wall (Kühn et al., 1994b). Though similar results were 
obtained in human atherosclerotic lesions, the share of 12/15-LOX product is much reduced 
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(Folcik et al., 1995; Kühn et al., 1997). Added to this is the clarification of the exact 
enzymatic nature of the oxLDL formation as several other enzymatic systems such as 
cytochrome P450, myeloperoxidase and cyclooxyneases and non-enzymatic process can 
confuse the results.  
Contrasting data showing the anti-atherogenic effects also exist. 15-LOX transgenic rabbits 
developed significantly lesser amount of atherosclerotic lesions when fed western type diet 
(Shen et al., 1996). Experimental anaemia in rabbits causes the overexpression of 12/15-LOX 
and these animals fed on cholestrol rich diet developed fewer lesions as compared to control 
animals (Trebus et al., 2002). Similar effects were also seen in mice (Paul et al., 1999). 
Atherosclerosis is a complex disease requiring the interplay of several factors and the 
elucidation of the role of 12/15-LOX in this process requires intensive research. 
1.6.6 Diabetes 
Another area in which the role of 12/15-LOXs have been studied is diabetes melitus. In type I 
insulin dependent diabetes, the insulin producing β islet cells in the pancreas are destroyed by 
a cytokine dependent autoimmune process. The cytokines primarily involved are IL-1β, IFNγ 
and TNFα and according to current hypothesis, this is achieved via the activation of nitric 
oxide (NO) (Eizirik and Mandrup-Poulsen, 2001). IL-1β upregulates the expression of 12/15-
LOX in rat insulinoma cell lines and in freshly isolated islet β cells (Bleich et al., 1995). 
Increase in the 12/15-LOX mRNA, protein and 12-HETE were observed post IL-1β 
treatment. Some authors have, however, argued that this increase in 12-HETE production is 
due to increased substrate availability facilitated by NO mediated pathways rather than an 
upregulation of the enzyme activity as such (Ma et al., 1996). 12/15-LOX deficient mice have 
been observed to be highly resistant to streptozotocin induced diabetes (Bleich et al., 1999) 
and increase in 12-HETE levels were observed in patients suffering from this disease 
(Antonpillai et al., 1996). 12/15-LOXs are lipid peroxidising enzymes and have the ability to 
generate free radical mediated oxidative stress. Rat insulinoma cells, Rin m5F, transfected 
with cGPx earlier demonstrated as an antagonist of 12/15-LOX, show increased resistance to 
cytokine induced apoptosis and necrosis (Lortz et al., 2000). Cells transfected with other 
antioxidant enzymes such as, superoxide dismutase and catalase also show similar resistance 
(Tiedge et al., 1999).  
A different picture emerges of the role of 12/15-LOX in type-II, non-insulin dependent, 
diabetes. Hepoxilin induces the production of insulin when injected in rats (Pace-Asciak et 
al., 1999) and 12-HETE also induces the production of glucagon from the α cells (Falck et 
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al., 1983). Thus, the exact role of 12/15-LOX in both types of diabetes needs to be elucidated, 
preferably by the use of specific inhibitors. 
 
1.7 Apoptosis 
Apoptosis, or programmed cell death, is considered a normal physiological process and a 
major form of cell death that is used to remove damaged or infected cells throughout the life. 
Apoptosis is also a mechanism by which the organism deals with stress, injury and factors 
threatening its integrity such as infection. Apoptosis is therefore important in normal cell 
development, occurring during embryogenesis as well as in the maintenance of tissue 
homeostasis (Nagata, 1997).  
 
Figure 6. Overview of apoptotic signalling pathways. 
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1.7.1 General mechanisms of apoptosis: 
Apoptosis is a regulated physiological process leading to cell death characterized by cell 
shrinkage, membrane blebbing and DNA fragmentation (Kerr et al., 1972). Caspases, a 
family of cysteine proteases, are central elements of apoptosis. Initiator caspases (including 8, 
9, 10 and 12) are closely coupled to pro-apototic signals. Once activated, these caspases 
cleave and activate downstream effector caspases (including 3, 6 and 7) which in turn cleave 
cytoskeletal and nuclear proteins and induce apoptosis (Thornberry and Lazebnik, 1998). 
Principally two pathways initiate the signalling cascade that results in apoptosis.  
 
1.7.1.1 Intrinsic pathway: This pathway is triggered in response to DNA damage, oxidative 
stress, chemotherapeutic agents and other types of stress (Vaux, 2002). It involves the Bcl-2 
family of proteins which consists of pro- and anti-apoptotic members (Gross et al., 1999). The 
anti-apoptotic members such as Bcl-2 and Bcl-XL exist in the mitochondria (Kluck et al., 
1997; Vander Heiden et al., 1997). Upon receiving the stress signal, the pro-apoptotic 
memebrs (bax, bid, bak, PUMA) translocate to the mitochondria and neutralise the anti-
apoptotic members by oligomerisation (Shimizu et al., 1999; Rosse et al., 1998; Luo et al., 
1998). This results in the permeabilisation of the membrane resulting in the release of 
apoptogenic factors such as SMAC/Diablo, cytochrome c, SIMPs and AIF (Garl and Rudin, 
1998; Matsuyama and Reed, 2000). Cytochrome c binds to APAF-1 to form the apoptosome 
resulting in the cleavage of caspase-9 and progression of the cascade via the effector caspases 
(Li et al., 1997). 
A number of pro-apoptotic stimuli including FasL, TNF, DNA damage and ER stress can 
initiate this pathway (Budihardjo et al., 1999; Nagakawa, 1999). Cytosolic p53, induced by 
DNA damage, has been observed to activate bax, PUMA, Noxa mitochondrial translocation 
(Oda et al., 2000). This process can be inhibited by the overexpression of Bcl-2 and Bcl-XL 
(Camilleri-Broet et al., 2000). Fas ligand or TNF receptors can also induce apoptosis utilising 
both intrinsic and extrinsic pathway (Scaffidi et al., 1998). The caspase-8 activated by these 
signals cleaves Bid which then translocates to the mitochondria to bind to Bcl-XL triggering 
cytochrome c release (Li et al., 1998). ER stress leads to the calcium-mediated activation of 
caspase 12 and proceeds via the cleavage of caspase-3 (Nagakawa, 1999). Anti-apoptotic 
ligands including growth factors and cytokines activate AKT kinase and p90RSK, which 
inhibit Bad and prevent cytochrome c release (Bonni et al., 1999; Datta et al., 1999). TNFR 
can also stimulate an anti-apoptotic pathway by inducing IAP, which directly inhibits 
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caspases 3, 7 and 9 (Roy et al., 1997). AIF (apoptosis inducing factor) released from the 
mitochondria (like cytochrome c) can directly bind to the nuclear DNA and induce its damage 
leading to cell death (van Loo et al., 2002). 
 
1.7.1.2 Extrinsic pathway: This pathway is used in a number important physiological 
functions such as cytotoxic T cell mediated apoptosis. External signals such as FasL 
(produced by cytotoxic T cells on their surface) and TNFα can activate pathway specific 
receptors of the TNF superfamily known as death receptors (TNF-R1, CD95, TRAIL R1 and 
R2) (Baker and Reddy, 1998; Ashkenazi and Dixit, 1998). The receptor oligomerisation 
results in the recruitment of specific adapter proteins such as FADD, TRADD, RIP and 
DAXX (Chinnaiyan et al., 1995; Hsu et al., 1995; Yang et al., 1997; Chaudhary et al., 1997). 
This complex is designated as DISC (death- inducing signalling complex). The formation of 
DISC leads to the recruitment and cleavage of pro-caspase-8 and 10 to their active forms. 
Caspase-8 and 10 function as initiator caspases leading to the activation of effector caspases. 
Cells can be divided into type I and type II depending upon the pathway utilised by activated 
caspase-8 (Scaffidi et al., 1998). In type I cells, sufficient amounts of caspase-8 exists and 
therefore directly cleave the effector caspases. While the type II, as described earlier, due to 
limited amounts of caspase-8, the mitochondrial amplification step is utilised.   
 
1.7.2 Potential role of 12/15-LOX in apoptosis: 
Arachidonic acid and its lipoxygenase and cyclooxygenase products have been observed to 
modulate apoptosis signalling (Tang et al., 2002). This occurs either by various metabolites of 
the AA cascade acting as ligands for signalling pathways or via the generation of oxidative 
stress by lipid hydroperoxides. 12/15 lipoxygenases can act on both free fatty acid and on 
membrane phopholipids to produce lipid hydroperoxides. In rat glioma cells, it has been 
observed that glutathione depletion leads to increased production of 12/15-LOX and causes 
cell death (Higuchi and Yoshimoto, 2002). NSAIDs induce the expression of 15-LOX-1 in 
colorectal and gastric cancer cells and trigger apoptosis ((Shureiqi et al., 2000; Wu et al., 
2003). SC-236, a specific inhibitor of COX-2 induced 15-LOX-1 and 13-HODE production 
(not 15-HETE) and initiated apoptosis in gastric cancer cells (Wu et al., 2003). Apoptosis was 
abolished by the inhibition of 15-LOX-1. Sodium butyrate treatment of rat intestinal epithelial 
cells led to differentiation and apoptosis, induction of 12/15-LOX has been suggested to be 
involved in this process (Kamitani et al., 1999). Treatment of RBL2H3 cells with 2-
deoxyglucose leads to the production of lipid hydroperxides and subsequent apoptosis. 
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Overexpression of the mitochondrial form of PHGPx, a scavenger of  lipid hydroperoxide 
radical, led to the reduction in hydroperoxide levels and suppression of apoptosis (Imai et al., 
1996; Nomura et al., 1999). Similar protection against apoptosis by PHGPx was observed in 
rabbit aortic smooth muscle cells challenged with linoleic acid hydroperoxide (Brigelius-
Flóhe et al., 2000).  
Increased levels of 12-HETE, produced by the reduction of 12-HpETE by glutathione 
peroxidase has been observed in several cancers and is correlated to their metastaic potential 
(Tang and Honn, 1999). Overexpression of 12-LOX platelet type enzyme in MCF-7 
mammary carcinoma cells, in human prostate adenocarcinoma cells resulted in cell 
proliferation and larger tumors (Liu et al., 1996; Connolly and Rose, 1998). Inhibition of 12-
LOX platelet type enzyme by NDGA and other inhibitors in Walker 256 carcinoma cells, 
gastric cancer cells and in lewis lung carcinoma cells resulted in the growth inhibition and 
apoptosis  (Wong et al., 2001; Tang et al., 1997; Honn et al., 1994b). Similar effect has also 
been observed in melanoma and prostate cancer cells (Onoda et al., 1994; Pidgeon et al., 
2002). Thus, the two 12 lipoxygenase isoforms have opposite effects on cell proliferation and 
apoptosis. It could be argued that conversion of 12-HpETE to 12-HETE reduces the oxidative 
stress in the cell. Another possibility is that 12-HETE functions as a ligand for proliferative 
pathways. AA and its products act as ligands for PPAR and other receptors. These receptors 
could have variable effects on cell proliferation. 
 
1.7.3 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the 
nuclear receptor gene family and are important regulators of fatty acid metabolism. PPARs 
act in a similar manner to other nuclear hormone receptors (Kersten et al., 2000). First, they 
bind a specific element in the promoter region of target genes. PPAR bind to the promoter as 
a heterodimer with retinoid X receptor (RXR) (Gearing et al., 1993). Second, they activate 
transcription in response to the binding of ligand. Eicosanoids, fatty acids and synthetic 
compounds known as peroxisome proliferators act as ligands  to PPARs. 
Three PPAR isotypes have been identified: α,β and γ. Some ligands are shared by the three 
isotypes, such as polyunsaturated fatty acids and probably oxidized fatty acids. Several 
compounds bind with high affinity to PPARα, including long-chain unsaturated fatty acids 
such as linoleic acid, branched, conjugated and oxidized fatty acids such as phytanic acid and 
conjugated linolenic acid, and eicosanoids such as 8(S)-HETE and leukotriene (LT) B4. The 
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prostaglandin 15-deoxy-∆12,14-prostaglandin J2 is the most potent natural ligand of 
PPARγ. 12/15-LOX products 13-HODE and 15-HETE also act as ligands for this receptor 
(Kersten et al., 2000; Gearing v 1993; Hihi et al., 2002; Forman et al., 1995; Lehmann et al., 
1995). Much of the function of PPARs can be extrapolated from the identity of their target 
genes, which so far all belong to pathways of lipid transport and metabolism.  
The role of 12/15-LOX and PPARγ in atherosclerosis is quite confusing. PPARγ activation in 
monocytes and macropphages induce their apoptosis  (Chinetti et al., 1998) and PPARγ 
liagnds reduce the development of atherosclerotic lesions in LDL-receptor knockout mice 
indicating anti-atherosclerotic effect (Li et al., 2000). While, pro-atherosclerotic effect was 
the induction of CD36, a scavenger receptor of oxLDL by IL-4 and 12/15-LOX induced 
PPARγ activation (Huang et al., 1999). This was clearly demonstrated by the lack of CD36 
induction in 12/15-LOX deficient mice and in PPARγ deficient stem cells (Chawla et al., 
2001). 
PPARγ activation has also been implicated in lung diseases. Increased PPARγ activation was 
observed in asthmatic patients as compared to normal controls and was correlated to 
apoptosis, airway remodelling and inflammation (Benayoun et al., 2001). Further, PPARγ 
agonists induced apoptosis in human lung carcinoma cells (Theocharis et al., 2002; Satoh et 
al., 2002; Inoue et al., 2001; Tsubouchi et al., 2000). Activation of death receptors, 
specifically TRAIL and inhibition of anti-apoptotic subunit of NF-κB p65/RelA have been 
implicated in PPARγ induced apoptosis, especially in macrophages (Chinetti et al., 1998; Ji et 
al., 2001).    
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2. Aim and objectives of the study 
Lipid mediators such as, leukotrienes, prostaglandins, lipoxins and lipoxygenase metabolites 
are important constituents of inflammatory process. Of these, 12/15-lipoxygenase and its 
metabolites were observed prominently in bronchial inflammatory diseases like asthma and 
bronchitis. Th2 cytokines, IL-4 and IL-13, have been observed to induce the expression of the 
12/15-LOX and are also present in bronchial inflammatory conditions. The 12/15-LOX 
metabolites, especially 15-HETE and 13-HODE, have been observed to function as ligands 
for nuclear receptor/transcription factor PPARγ. The exact nature of the influence these 
factors have in the pathogenesis of inflammatory bronchial diseases is not clear. The enzyme 
has also been implicated in other disorders such as insulin dependent diabetes. In rat β islet 
cells, novel metabolites of 12/15-LOX, hepoxilins, have been observed though the pathways 
involved in their biosynthesis are little understood.  
I. The aim of the study was to characterise the mechanism of induction of 12/15-LOX 
expression by IL-4 in lung carcinoma cell line, A549. Experiments were aimed at elucidating 
the signal transduction pathways involved. Our main focus was on understanding changes 
occurring in the chromatin structure, especially histone modifications and the interaction 
between the various transcription factors and co-activators required for the induction of 
mRNA synthesis. 
II. One of the objectives of the study was to determine the role of 12/15-LOX enzyme and its 
metabolites in the apoptotic process, or cell death observed during bronchial inflammation. In 
particular, the nature of involvement of PPARγ and the characterisation of the downstream 
signalling steps leading to apoptosis. 
III. The nature of the biosynthetic pathway of hepoxilin was investigated in rat β islet cells. 
The intrinsic hepoxilin synthase activity of 12/15-LOX was examined along with the 
regulation of synthesis of hepoxilins. 
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3. EXPERIMENTAL PROCEDURES 
3.1 MATERIALS 
FATTY ACIDS AND EICOSANOIDS  
Arachidonic acid, linoleic acid, 12-HpETE, 12-HETE, 15-HETE, 13-HODE - Cayman 
(USA). 
CULTURE REAGENTS  
Fetal Calf Serum (FCS), Dulbecco’s Modified Eagles Medium (DMEM), Trypsin/EDTA, 
Streptomycin/Penicillin – Seromed (Germany); Yeast Nitrogen Base, Yeast extract, Tryptone, 
Peptone, Agar– Difco (USA). 
SEPARATION MEDIA 
Agarose – Roth (Germany); Silica gel-60 TLC plates – Merck (Germany); Rotiphorese 
acrylamide Gel 30 – ROTH (Germany);  Supesil silica HPLC column – Supelco (Germany), 
Novapak C18 RPLC column – VDS Optilab (Germany). 
KITS 
RNeasy Mini Kit and QIAshredder - Qiagen (Germany); Protein Determination kit – Biorad 
(USA); Chemiluminiscent system - Santa Cruz (Germany); Luciferase Reporter Assay – 
Promega (Germany); PolyFect Transfection Kit- Qiagen (Germany); Lipofectamine 2000 – 
Invitrogen (Germany); QuikChange kit – Stratagene (USA); Cell Death detection ELISA – 
Roche (Germany). 
ANTIBODIES  
Actin – Sigma (Germany); PPARγ – Cayman (USA); histone H3 and acetyl histone H3 –
Upstate, Germany; Bcl-XL – Calbiochem (Germany); Pan acetyl, STAT6, cytochrome c, 
porin VDAC,  Protein A agarose, anti-mouse, anti-rabbit, anti-goat secondary antibodies 
conjugated with horse radish peroxidase – Santa Cruz (Germany).  
RT-PCR REAGENTS 
Expand reverse transcriptase – Roche Biochemicals (Germany), Taq DNA Polymerase – AB 
Technologies (Germany), Pfu Turbo Polymerase – Stratagene (USA), Platinum Taq 
Polymerase – Invitrogen (Germany). 
CASPASE SUBSTRATE AND INHIBITOR 
Caspase-3 substrate Ac-DEVD-pNA and inhibitor Z-VAD-FMK – Calbiochem (Germany). 
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ENZYMES  
Proteinase K- Roche Biochemicals (Germany);  T4 DNA ligase-Gene Craft 
(Germany); Terminal deoxynucleotide transferase (TdT)- Pharmacia (Sweden); 
Restriction enzymes were obtained from NEB (USA). 
RADIOCHEMICALS  
14C-Arachidonic acid (55 mCi/mmol); 3H-Acetyl Coenzyme-A - Amersham 
(England). 
PRIMERS  
All primers were purchased from TIB Biomol (Germany). 
SEQUENCING 
Automated fluorescent DNA sequencing was performed by SeqLab (Germany). 
OTHER REAGENTS 
All organic solvents used in HPLC and GC-MS experiments were of LiChrosolv or 
SupraSolv quality, all other reagents were of analytical grade and were mainly obtained from 
Sigma Chemicals (Germany). 
 
       
3.2 Media  and Buffers 
LB MEDIUM  
10 g/L  Tryptone,  
5 g/L   Yeast extract,  
5 g/L  NaCl.  
The pH was adjusted to 7.2 and autoclaved. 
 
1x TBE 
10.8 g/L Tris base 
5.5 g/L Boric acid 
4 ml  EDTA (0.5 M) 
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3.3 Mammalian cell culture 
A549 cells (DSMZ, Braunschweig, Germany) and HeLa (DSMZ, Braunschweiz, Germany) 
were cultured in Dulbecco’s Modified Eagle’s medium supplemented with 10 % fetal calf 
serum. Normal human bronchial epithelial cells (BEAS-2B) (ATCC, Washington D.C., USA) 
were cultivated in a modified LHC-9 medium with 0.5 ng/ml recombinant epidermal growth 
factor (EGF), 500 ng/ml hydrocortisone, 0.005 mg/ml insulin, 0.035 mg/ml bovine pituitary 
extract, 500 nM ethanolamine, 500 nM phosphoethanolamine, 0.01 mg/ml transferrin, 6.5 
ng/ml 3,3',5-triiodothyronine, 500 ng/ml epinephrine, 0.1 ng/ml retinoic acid and trace 
elements as supplied by Clonetics Corporation, USA. Rinm5F, rat  insulinoma cells (ATCC, 
Washington D.C., USA), was cultured in RPMI 1640 medium supplemented with 10 % fetal 
calf serum. The cells were grown in humidified incubators at 37 0C with 5 % CO2.  
 
3.3.1 Transient and stable transfection of cell lines 
Transient transfection of DNA was performed in A549 and HeLa cells using Polyfect 
transfection reagent (Qiagen, Germany). 5x105 cells were seeded into 35 mm tissue culture 
plates. Next morning, 1.5 µg of plasmid DNA was mixed with 12 µl of Polyfect reagent in 
100 µl antibiotic free medium and DNA-liposome complexes were allowed to form at room 
temperature for 20 minutes. The complexes were gently seeded onto the cells and incubated 
at normal conditions for 24 h. The cells were used for further experiments at the end of this 
period. For Rinm5F cells, Lipofectamine 2000 reagent was utilised along with 1 µg of DNA. 
The cells were cotransfected with 0.1 µg of control plasmid pRSVLACZ to normalise for 
transfection efficiency by performing β-galactosidase assay. 
Stably transfected cells were achieved by transferring transiently transfected cells into 
medium containing restrictive antibiotic G418 (Invitrogen, Germany). For HeLa cells 800 
µg/ml and for Rinm5F cells 700 µg/ml of G418 was used. Individual colonies of G418 cells 
were separately grown for at least 1 month in the antibiotic. After this period, the cells were 
transferred and maintained in medium containing half the selective concentration of the 
antibiotic. The clones expressing highest amount of foreign protein as evidenced from 
Western blotting were used for further experiments. Sodium selenite (Sigma, Germany) 10 
nM was supplemented into the medium in the case of Rinm5F cells transfected with cGPx or 
PHGPx. Rinm5F stably transfected with cytosolic glutathione peroxidase (cGPx), kind gift 
from Dr. Tiedge, Hannover, Germany, were cultures in the same culture medium as above 
supplemented with 350 µg/ml G418 (Invitrogen) and 10 nM sodium selenite. 
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3.4         Plasmids  
Plasmids wt E1A, mCBP and mRb were kind gifts of Dr. A. Hecht, Freiburg, Germany. wt 
E1A consists of 2 domains which bind to CBP and Rb proteins and inhibit their actions. 
Plasmid mCBP is the E1A protein from which the CBP binding domain has been mutated and 
in the mRb protein the Rb binding domain has been mutated (Hecht et al., 2000). 
 
 
 
 
 
 
 
 
 
PPARγ dominant negative plasmid was a kind gift from Prof. V.K.K. Chattejee, Oxford 
University, UK. The plasmid contained the complete PPARγ tagged with FLAG in which 
leu468 was mutated to Ala and Glu471 was mutated to Ala (Adams et al., 1997). The mutant 
protein retains the ligand and DNA binding activity but has no transactivating activity because 
of impaired binding to the coactivators like CBP and steroid receptor coactivator-1. 
FADD dominant negative vector was a kind gift from Dr. M.L. Schmitz, Heidelberg, 
Gemany. In this plasmid death effector domain (N terminal 80 amino acids) truncated FADD 
protein was expressed which even though could bind to the death receptors, could not 
propagate the signal by its inability to bind to caspase-8 (Hofmann et al., 2001). 
PHGPx overexpression vector was a kind gift from Prof. R. Brigelius-Flóhe, Potsdam, 
Germany. The complete PHGPx gene along with the regulatory 3’UTR was cloned into 
pcDNA3 (Brigelius-Flóhe et al., 1997).   
Other plasmid were constructed in the laboratory by cloning required fragments and all the 
fragments and the cloning procedure was confirmed by DNA sequencing (SeqLab, Germany). 
Peroxisome prolifator response element (PPRE) was PCR amplified and cloned in pGL3 basic 
vector (Promega) at the Kpn 1 and Hind III sites. 
12/15-LOX was amplified from rat cDNA by PCR and cloned into mammalian expression 
vector pcDNA3 (Invitrogen) at  the BamHI and XhoI sites and into pET15b bacterial 
expression vector (Novagen) at the Nde I and Xho I sites.  
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3.5 Western blotting 
 
3.5.1 Preparation of total protein from cells  
Cells were lysed directly on the plates by the addition of  protein lysis buffer containing 50 
mM Pipes/HCl (pH 6.5), 2 mM EDTA, 0.1% Chaps, 20 µg/ml Leupeptin, 10 µg/ml Pepstatin 
A,10 µg/ml Aprotinin , 5 mM DTT and 1 mM PMSF (Cell Technologies, USA). The cells 
were scraped and lysed by freezing and thawing 3 times. The mixture was centrifuged at 
10,000xg at 4 0C for 15 minutes to remove the cell debris. Protein concentration was 
determined using a modified Lowry‘s method ( BioRad, germany). 
  
3.5.2 SDS-PolyAcrylamide Gel Electrophoresis and Immunoblotting 
10% SDS Polyacrylamide gel was prepared according to the following recipe. For the 
separating gel of 10 ml volume: 4 ml of distilled water, 2.5 of 1.5 M Tris-HCl (pH 8.8), 3.3 
ml of 30% Polyacrylamide mix (37.5:1 ratio of mono and bis acrylamide) (Roth, Germany), 
100 µl of 10% SDS, 100 µl 10% ammonium persulphate (APS) and 15 µl N,N, N’,N’ 
tetramethylethylenediamine (TEMED). For 5 ml of stacking gel: 3.4 ml of distilled water, 
630 µl of 1 M Tris-HCl (pH 6.8), 830 µl 30% Polyacrylamide mix, 50 µl 10% SDS, 50 µl 
10% APS and 5 µl TEMED. The gel was cast in MiniProtean III apparatus (BioRad, 
Germany). The protein samples were mixed with SDS sample solution (Rotiload, Roth, 
Germany) and  boiled for 5 minutes for complete denaturation. This mixture was loaded onto 
the gel and electrophoresed Immunoblotting was performed utilising the semi dry transfer 
method. Nitrocellulose membrane (Schleisser and Schuell, Germany) and 6 layers of  
Whatman 3 paper were cut exactly to the size of the gel and soaked in transfer buffer along 
with the gel. A stack was made with 3 sheets on the top and bottom of the gel and membrane 
and placed in between the graphite plates of the transfer apparatus (Biometra, Germany). 
Transfer was performed at 0.8 mA/cm2 current for 1 hour. The efficiency of the transfer was 
confirmed by staining the membrane with a 0.1% solution (containing 1% acetic acid) of 
Ponceau S (Sigma, Germany). The excess stain was washed with water. After visualisation of 
the protein, the blot was completely washed off the stain with water and put into blocking 
solution (5% nonfat milk powder in PBS containing 0.05% Tween 20) for 1 h at room 
temperature. The blots were then incubated in the blocking solution containing 1:500 – 
1:1000 dilution of the primary antibody for 1h at RT. After washing in wash solution (PBS 
containing 0.05% Tween 20) for 10 minutes, the blot was incubated with the secondary 
antibody (against the species of the primary antibody and linked to horse radish peroxidase) 
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(1:5000 dilution) for 1 h at RT. After 3 washes of 5 minutes each with wash buffer, the 
specific bands were developed using Chemiluminiscent system (Santa Cruz, Germany). 
Equal volumes of solution A and B were mixed and the blot was incubated in this solution for 
1 minute. The blot was immediately exposed to an X-Ray film in dark for varying periods of 
time ranging from 5 sec to 2 min and automatically developed. The specific bands were 
scanned and quantified densitometrically using TINA version 2.09g. All immunoblots, were 
sequentially incubated with anti-β-actin as control, and specific signals adjusted in relation to 
the expression of this house-keeping gene. 
 
3.6 Cell fractionation 
3.6.1 Nuclear extract preparation 
Cells were washed with ice cold PBS, scraped and pelleted at 10,000xg, 4 0C. The pellet was 
resuspended in 400µl of hypotonic buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl2; 10 mM 
KCl) and incubated on ice for 15 minutes and simultaneously lysed with the addition of 100µl 
of 2.5% NP40. Nuclei were pelleted for 1 minute at 2000xg. The nuclear pellet was 
resuspended in protein lysis buffer (Dignam et al., 1983). 
 
3.6.2 Preparation of mitochondria  
Cells were washed twice with PBS, trypsinised and the cell pellet was collected. The pellet 
was resuspended in 5 volumes of homogenisation buffer (20 mM HEPES 7.5, 1.5 mM MgCl2, 
10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF and 250 mM Sucrose) 
and homogenised for 5 minutes using a tight fitting dounce homogeniser. The whole 
procedure was carried out at 4 0C. The effectivity of the procedure was checked by trypan 
blue exclusion test. Nuclei and cell debris were pelleted at 2,000xg. Mitochondria were 
pelleted by centrifugation at 10,000xg for 30 minutes at 4 0C. The pellet was resuspended in 
protein lysis buffer (3.5.1). The supernatant was further centrifuged at 100,000xg for 45 
minutes at 4 0C. The supernatant was used as the cytosolic extract. Protein concentration was 
determined both in the mitochondrial and cytosolic fractions. Equal amounts of protein were 
used for further experiments.  
 
3.7 Immunoprecipitation 
Immunoprecipitaions were performed by incubating the protein extracts with 2 µg of the 
primary antibody for 1 hour at 4 0C. The immune complexes were incubated with protein-A 
agarose (Santa Cruz) for 1 hour at 4 0C. The beads were spun down (2500xg, 2 min, 40C), 
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washed 3 times with RIPA buffer (1% nonidet P40, 0.5% deoxycholate, and 0.1% SDS in 
PBS) and the immune complex released by boiling in SDS sample solution and 
electrophoresed. The proteins were eluted from the beads with elution buffer (1% SDS in 0.1 
M NaHCO3) when subsequent immunoprecipitations or reactions were to be performed. 
 
3.8 Chromatin immunoprecipitaion 
Formaldehyde was added to the cells at a final concentration of 1% and incubated for 20 
minutes at room temperature. The reaction was stopped by the addition of glycine to a final 
concentration of 0.125M. The cells were washed with cold PBS and harvested. The nuclear 
extract was prepared according to Dignam et al., 1983 and sonicated at maximal power for 30 
seconds twice to shear the genomic DNA. Immunoprecipitations were performed with various 
antibodies. Crosslinking was reversed in the immunoprecipitated complexes by the addition 
of NaCl to a final concentration of 200 mM and incubation at 65 0C for 6 hours. The DNA 
was purified by proteinase K treatment (150µg/ml) for 1 h followed by phenol/chloroform 
extraction and precipitation by ethanol. The presence of specific promoter were detected by 
PCR with specifc primers. The extract aliquoted prior to the immunoprecipitaions was used to 
prepare control input genomic DNA, which was also used for PCR analysis. For Western 
blotting, protein was directly denatured by electrophoresis sample buffer and applied to SDS-
PAGE. 
 
3.9 RNA preparation  
Total RNA was prepared using RNAsy kit fom Qiagen, Germany. Cells were washed with 
PBS 3 times and lysed in 350 µl RNA lysis buffer and sonicated at maximum wattage for 30 
seconds. The lysate was mixed with equal volumes of 70 % ethanol and loaded onto the 
column. The column was spun at maximum speed for 15 seconds at RT. The column was 
washed with RW1 and PR1 buffer and RNA was eluted in 30 µl Rnase free water by 
centrifugation and stored at –80 0C. 
 
3.10 Reverse transription and polymaerase chain reaction 
Reverse transcription was performed using 5 µg of RNA which was denatured at 65 0C for 10 
minutes and to which reaction buffer, 1,5 mM MgCl2,1 mM dNTPs, 20 mM DTT, 50 pmoles 
of (dT)18 primer and 1 µl of AMV reverse transciptase (Roche, Germany) was added. The 
reaction was performed at 42 0C for 1h. 1/20th of the resultant cDNA was used in the 
subsequent PCR reaction. PCR was performed with 5 pmoles of forward and reverse primer, 
Experimental Procedures  
 
33
200 µM of each dNTP and 1 U of Taq polymerase. For quantitative PCR, 25 cycles were used 
and for normal PCR 35 cycles were used. β-actin primers were used to perform control 
reactions to quantitate the product formed. Genomic PCR was performed using  10 ng of 
genomic DNA as template. Negative and positive controls were used with each set of PCR 
reaction. The primers and reaction conditions are listed below. 
STAT6 element of 15-LOX-1 gene: 
5‘ GTGGGGTGGTGGGGGGTGAAAG 3‘   
5‘ CTCCTCACCTCTCATCCCACTGC 3‘  
94 0C 3min; 94 0C 30 s, 55 0C 30 s, 72 0C 30 s for 35 cycles; 72 0C for 7 min, 4 0C. 
 
15-LOX-1 promoter (1 kb): 
5‘ AAGCTAATTCACTCTGGTGGGGTGG 3‘  
5‘ AAGATGTTTCGCTCCTTCTGGAGG 3’ 
94 0C 3min; 94 0C 30 s, 55 0C 30 s, 72 0C 1 min for 35 cycles; 72 0C for 7 min, 4 0C. 
 
Human Peroxisomal Fatty Acyl Coenzyme A Oxidase Gene containing PPRE: 
5‘ CGGAAGCTTCGCGACGACCAGCTGGC 3‘   
5‘ GGCAGATCTTACGTTGACGTGAGGTCGG 3‘ 
94 0C 3min; 94 0C 30 s, 60 0C 30 s, 72 0C 2.5 min for 35 cycles; 72 0C for 7 min, 4 0C. 
 
Rat 12/15 lipoxygenase gene: 
5’ CGACATATGTGTCTACCGCATCCGC 3’ 
5’ TGGCTCGAGTCAGATGGCCACGCTGTT 3’ 
94 0C 3 min; 94 0C 1 min, 55 0C 1 min, 72 0C 2 min, 35 cycles; 72 0C 7 min; 4 0C. 
15-LOX-1 cDNA : 
5' GGGGCTGGCCGACCTCGCTATC 3'  
5' TCCTGTGCGGGGCAGCTGGAGC 3' 
94 0C 3 min; 94 0C 1 min, 72 0C 1 min, 35 cycles; 72 0C 7 min; 4 0C 
 
The PCR mixture was mixed with DNA loading buffer and electrophoresed in 2% agarose gel 
in 1x TBE at 7 volts/cm of gel. DNA was visualised under UV after staining the gel with 0.5 
µg/ml of ethidium bromide. 
 
3.11 Electrophoretic Mobility Shift Assay (EMSA) 
Double stranded oligonucleotide containing the transcription factor binding element was used 
as probe in the gel shift assays. The assays were performed with nuclear extracts. The 
oligonucleotide was made double stranded by heating the mixture of the two strands at 94 0C 
for 5 minutes and then was allowed to cool down slowly to RT. The probe was labelled with γ 
32P ATP (sp. activity 3000 Ci/mmol) using T4 polynucleotide kinase at 37 0C for 30 minutes. 
Protein was incubated with 30,000 cpm of labelled oligonucleotide in a buffer containing 10 
µM Tris pH 7.5; 1 mM EDTA; 100 mM NaCl; 5 % glycerol  along with 1 µg of Poly dIdC 
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(Roche, Germany) for 20 minutes at RT in the presence or absence of various competing 
oligonucleotide sequnces (Schreiber et al., 1989). The  reaction mixture was electrophoresed 
on a 6% PAGE in 1xTBE and visualised by autoradiography. 
3.12 Reporter assay 
3.12.1 Luciferase assay   
The cells were washed twice with ice-cold PBS and lysed with 100 µl luciferase lysis buffer 
(Promega, Germany). The lysis was completed by freezing and thawing 3 times and after 
centrifugation the supernatant was utilised for assay of luciferase and β-galactosidase. 
Luciferase assay was performed by vortexing 5 µl of the extract with 50 µl of luciferase assay 
solution (Promega, germany) and the bioluminescence was measured by scintillation 
counting. 
 
3.12.2 β-galactosidase assay 
For quantification of β-galactosidase activity, 50 µl of the extract was incubated at 370C for 
10 min, then 100 µl  of pre-warmed 4 mg/ml o-nitrophenyl para-D-galactopyranoside 
(ONPG) in 0.1 M sodium phosphate buffer (pH 7.5) was added. After a suitable time of 
reaction, 300 µl  of 1 M Na2CO3 was added, and the absorbance at 420 nm of the solution was 
measured with a spectrophotometer. The β -galactosidase activity was expressed as ONPG 
unit (1 unit: the activity producing 1 mmol o-nitrophenol per minute, normalised against the 
inoculated cell number). The β -galactosidase activity was determined as the average value 
from triplicate dishes under the same transfection conditions. 
  
3.13 DNA affinity chromatography 
The specified DNA was amplified by PCR. 100 pmoles of this DNA was end labelled with 
biotin16-dUTP using terminal deoxynucleotide transferase (TdT) enzyme (Pharmacia, 
Germany). The end labelled DNA was purified by ethanol precipitation and bound to 
streptavidin-coated magnetic beads (Roche, Germany). 100 µl of the beads were washed 3 
times with 100 µl of DNA binding buffer (10 µM Tris pH 7.5; 1 mM EDTA; 100 mM NaCl ) 
and each time the beads were collected using magnetic particle collector (Dynabeads, 
Sweden). The biotin labelled DNA was mixed with the bead with at least 2 volumes of DNA 
binding buffer. The mixture was kept at 4 OC with vigorous shaking for 10 minutes. The 
magnetic particles were collected and washed  3 times with DNA wash buffer (10 µM Tris pH 
7.5; 1 mM EDTA; 1 M NaCl). The beads were further washed 3 times with 100 µl of protein 
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binding  buffer (10 µM Tris pH 7.5; 1 mM EDTA; 100 mM NaCl; 5 % glycerol). The beads 
were incubated with 100 µg of protein in protein binding buffer containing 10 µg of Poly 
dIdC. The incubation was performed under continuous shaking at 4 0C for 1h. The beads were 
once again collected and washed 3 times with protein binding buffer. The specifically bound 
proteins were eluted using protein binding buffer containing 2 M NaCl. The solution was 
desalted by overnight dialysis against PBS at 4 0C and electrophoresed on SDS-PAGE. 
 
3.14 In vitro histone acetyltransferase (HAT) assay 
Filter binding assays were performed as described (Ogryzko et al., 1996) with minor 
modifications. 3.3 mg/ml of histones (Sigma) were acetylated in a reaction buffer containing 
50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10 % glycerol, 1mM PMSF. (3H) acetyl CoA 
(Amersham, UK) and 6 µg of protein extract for 30-60 minutes at 30 0C. The reaction mixture 
was spotted onto P81 phosphocellulose paper (Upstate Biotechnology, USA) and washed for 
30 minutes with 0.2 M carbonate buffer (pH 9.2). The filter paper was dried and used for 
liquid scintillation counting. Similar experiments were performed using non-radioactive 
acetyl-CoA.. The reaction mixture was denatured and loaded onto a SDS PAGE. The Western 
blot was probed with anti-acetylhistone H3 antibodies and developed using Chemiluminiscent 
detection system. 
 
3.15 Assays for apoptosis 
3.15.1 Cell Death ELISA 
Cell Death Detection ELISA kit (Roche Biochemicals, Germany) was also used to quantify 
the apoptosis in cells. The cells were lysed by a hypotonic solution and the cytoplasmic 
extract was incubated with anti-histone and anti-DNA antibodies. The complexes bound to 
the ELISA plate were quantified using horse raddish peroxidase enzyme and DTNB reagent. 
104 cells were plated on 96-well plates in DMEM medium. Effectors or inhibitors of 
apoptosis were added, and apoptotic cell death was determined after 72 hours with above 
mentioned ELISA kit. 
 
3.15.2 Annexin-V assay 
For the annexin-V assay, cells grown on glass coverslips were washed with PBS and 
incubated for 15 minutes at room temperature with a solution of annexin-V fluos and 
propidium iodide (Roche Biochemicals, Germany). Cells were then washed twice with PBS 
and observed under a fluorescence microscope. Normal cells do not get stained at all, while 
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apoptotic cells are stained green (annexin-V fluos) and necrotic cells red (propidium iodide). 
Fluorescence microscopy was performed with a BX-40 Olympus microscope witha mercury 
lamp, appropriate filter set and automatic photomicrography attachment. A minimum of 200 
cells were counted.  
 
3.15.3 TUNEL assay  
TUNEL assay was performed by washing paraformaldehyde-fixed (4% paraformaldehyde in 
PBS for 30 minutes at RT) cells on coverslip 3 times with PBS and then permeabilized using 
0.5% saponin at room temperature for 30 min. After washing with TdT buffer cells were 
incubated with 0.5 µM biotin dUTP, 150 U /ml TdT in 30 µl TdT buffer (Roche 
Biochemicals, Germany) in a humidified chamber at 37 0C for 30 minutes. After washing 
twice with PBS, the cells were incubated with 1:1000 solution in PBS of streptavidin-
conjugated horse radish peroxidase (GIBCO, Germany) for 10 minutes at room temperature. 
Coverslips were then washed for 30 minutes with 3 washes of PBS. The colour was 
developed with True Blue (KPL Labs, Germany) peroxidase substrate, and coverslips were 
observed under a light microscope. Apoptotic cells were stained blue.  
 
3.15.4 Caspase-3  assay  
Caspase-3 assay was performed using Ac-DEVD-pNA as substrate. Cells were lysed with 
lysis buffer (50 mM HEPES, pH7.4, 100 mM NaCl, 0.1 % CHAPS, 1 mM DTT, 100 µM 
EDTA) and centrifuged at 10,000xg for 10 min. 100 µg of protein were incubated with 200 
µM solution of Ac-DEVD-pNA (Calbiochem, Germany) in reaction buffer (lysis buffer with 
10 mM DTT and 10% glycerol) at 37 0C. The development of yellow colour at 405 nm 
indicated caspase-3 activity. The reaction was monitored periodically for 3-4 hours. The rate 
of reaction was calculated as difference in the absorbance at 405 nm per unit time. The results 
were represented as fold increase in caspase-3 activity over the control reactions. Z-VAD-
FMK (Calbiochem, Germany) was used as inhibitor of caspase-3 at a concentration of 100 
µM an hour prior to standard treatment. 
 
3.16 Detection of PPARγ  ligand  
Labelled fatty acids as ligands to PPARγ were detected by immunoprecipitating the PPARγ in 
pre-treated cells and then detecting the fatty acid attached to it by radio-TLC. Cells (1x 106) 
were incubated with 0.25 µCi of [14C]-arachidonic acid [sp. act. 55 mCi/mmol] (Amersham, 
Germany) for 24 hours. After the incorporation of the radioactive arachidonic acid (AA), cells 
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were washed and treated according to  experimental set-up. Cell lysate was prepared and 
immunoprecipitated with anti-PPARγ antibody in 1 ml RIPA buffer for 1 hour at 4 0C. The 
immune complexes were allowed to bind to protein A agarose (Santa Cruz) for 1 hour. The 
beads were spun down, washed 3 times with RIPA buffer and resuspended in 200 µl of PBS. 
This solution was acidified with HCl to pH 3.5 and lipids were extracted 3 times with ethyl 
acetate. After drying under nitrogen stream the sample was reconstituted in ethyl acetate and 
loaded onto a Silica TLC plate (Merck, Germany) and developed with hexane:ether:acetic 
acid (50: 50 : 0.1 v/v) as solvent system. For quantitation, the TLC plate was scanned on 
radio-TLC scanner (Berthold Instruments, Germany). AA, 5-, 12- and 15-HETEs and various 
prostaglandins were run on the side as standards.   
 
3.17 High Performance Liquid Chromatography analysis (HPLC)  
Purified proteins or cell extracts in PBS were incubated with arachidonic acid (100µM) the 
reaction was allowed to proceed at 37 0C for 20 minutes. Reduction of hydroperoxy fatty 
acids to their corresponding hydroxy derivatives was achieved by the addition of a molar 
excess of sodium borohydride. The reaction mixture was acidified to pH 3.5 and lipids were 
extracted with an equal volume of ethyl acetate. Straight phase HPLC analysis was performed 
on a Supelco-SIL column (250 x 4.6 mm, 5 µm) using n-hexane: 2-propanol: acetic acid 
(100:2:0.1, by vol.) as mobile phase at a flow rate of 1 ml/min. reverse phase HPLC was 
performed on a Novapak C18 reverse phase column and 80 : 20, acteonitrile : water as the 
running buffer. Conjugated dienes were detected and quantified at 235 nm using a diode array 
detector (Shimadzu).  
 
3.18 Assay of hepoxilin A3 synthase activity 
The hepoxilin synthase A3 activity was measured by incubating the purified protein or cell 
lysate with  20 µM 12(S)-HpETE in a volume of 200 µl for 30 minutes at 37 OC and 
measuring the formation of hepoxilins using GC-MS or HPLC. The reaction was stopped by 
acidification with 1N HCl to pH 3.0 The reaction mixture was allowed to incubate at room 
temperature in acidic conditions for 15 minutes before extracting the lipids twice with 3 
volumes of ethyl acetate. The lipid fractions were extracted with ethyl acetate, evaporated to 
dryness under nitrogen, reconstituted in n-Hexane and analysed with GC-MS.  
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3.18.1 Gas chromatography-Mass spectrometry (GC-MS)  
The lipids were converted to their methyl esters by the addition of  300 µl ethereal 
diazomethane for 5 min. Thereafter the samples were evaporated to dryness, 30µl N-methyl-
N-(trimethylsilyl)trifluoroacetamide (MSTFA) were added and the mixture was derivatised 
by heating at 60oC for 30 min. Gas chromatography-mass spectrometry (GC-MS) was 
performed by means of a Varian Saturn 4D GC-MS-MS system equipped with a Supelco 
DB5-MS column (30 m x 0.25 mm; 0.25 µM df).  The temperature program was started at 
150oC increasing to 250oC within 10 min with a rate of 10oC/min.  The temp. of injector and 
transfer line were 230oC and 220oC respectively. 
 
3.18.2    Detection of hepoxilin A3 by HPLC 
Protein was incubated with 100 µM AA at 37OC for 30 minutes. The reaction was stopped 
and the lipids were extracted by the addition of ether-methanol-1M citrate (135:15:1, v/v). 
The organic phase was evaporated and the residue was taken into 100 µl ethyl acetate and 
derivatised by the addition of 9-Anthryldiazomethane (100 µg/reaction) (Reynaud et al., 
1994). The reaction mixture was stirred at room temperature for one hour. The ethyl acetate 
was then evaporated, the residue was reconstituted in the solvent system and the lipids were 
loaded onto a Novapk C18 (250 x 46 mm; 5 µm particle size) reverse phase column. 
Acetonitrile-methanol-water (90:6:4 v/v) was used as mobile phase. The eluate was uv-
monitored using a Shimadzu diode-array detector set at 254 nm and fluorescence-monitored 
(excitation 254 nm, emission 400nm) using a Shimadzu fluorescence detector. 
 
3.19    Cloning of  rat 12/15-LOX 
Total RNA was extracted from Rinm5F cells using RNeasy kit and reverse transcribed using 
AMV reverse transcriptase enzyme. The reaction was performed at 42 0C for 45 minutes 
using a dT18 primer. Complete 12/15-LOX gene was amplified with Pfu Polymerase and 200 
µM dNTPs using primers as mentioned above. A small aliquot of the reaction was used for 
instant PCR cloning using TOPO TA cloning kit. The ligation was performed for 5 minutes 
and then E. coli DH5α was transformed with 2 µl of the ligation reaction using heat shock. 
The mixture was plated onto LB ampicillin plates and the white colonies were grown in 3 ml 
LB (80 µg/ml ampicillin), plasmid prepared and were screened for the presence of the insert 
using restriction enzymes. The positive clones were sequenced from both directions using 
M13 forward and reverse primers and automated fluorescent sequencing. The entire sequence 
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was compared with the published rat 12/15-LOX sequence (Accession number. NM_031010) 
using the Blast server (www.ncbi.nlm.nih.gov/Blast).  
 
3.20 Cloning and expression of rat 12/15-LOX in bacteria 
The 12/15-LOX gene insert was cloned into the Nde I and Xho I sites in PET 15b vector 
(Novagen). The positive colonies were screened and purified. For overexpression 
experiments, E. coli  BL21 DE3 cells were transformed with the plasmid. A 3 ml overnight 
culture was established from a single colony. Next morning, a 10 ml culture was cultivated in 
LB (80µg/ml ampicillin and 37 µg/ml chloramphenicol). The cells were grown till O.D. 0.6 
and then the recombinant protein production was induced by the addition of 1 µM IPTG for 3 
h at 37 0C. The bacteria was pelleted by centrifugation and resuspended in PBS. Lysis was 
performed by sonication. The lysate was used for all further experiments.  
 
3.20 Statisics 
All experiments were repeated at least three times and the representative pictures have been 
shown. The data were presented as mean ± SD. Statistical comparisons between groups were 
made using Student’s t test for paired observations. Significance was achieved at the p<0.05 
level. All calculations were performed at www. graphpad.com. 
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4. Results 
4.1 Transcriptional Regulation of 15-LOX-1 expression 
4.1.1 Induction of 15-LOX-1 expression in A549 human lung epithelial cells  
A549 cells were cultured for various time periods in the presence of 670 pM IL-4. The cells 
were harvested and the lysates were analysed for the expression of 15-LOX-1 mRNA by RT-
PCR using 15-LOX-1 specific primers. 15-LOX-1 mRNA was first observed after minimum 
12 h of IL-4 stimulation. The highest mRNA concentration was detected after a 24 h 
incubation period (Fig. 7A). After longer incubation periods the mRNA levels dropped 
perceptibly. To find out whether IL-4 has to be present during the entire incubation period or 
whether a single cytokine stimulus may be sufficient to induce 15-LOX-1 expression the 
following experiment was carried out. A549 cells were exposed to IL-4 for various time 
periods, the cytokine was washed away and incubation was resumed for a total of 24 h. 
Finally, the expression of 15-LOX-1 mRNA was analysed by RT-PCR.  
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β-actin 
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 Figure 7. Induction of 15-LOX-1 mRNA was delayed and requires continuous
exposure to IL-4. Panel A: A549 cells were incubated with 670 pM IL-4 in serum-free
medium for different periods (0-72 h), the cells were harvested, and total RNA was
extracted. Semiquantitative RT-PCR was performed to detect 15-LOX-1. β-Actin RT-
PCR was used for the normalization of 15-LOX-1 expression. Panel B: A549 cells were
exposed to IL-4 (670 pM) for varying periods (0-11 h). IL-4 was removed by washing
thrice with PBS, and incubation was resumed for a total of 24 h; then the cells were lysed
for RNA extraction. 15-LOX-1 expression was assayed by RT-PCR. 
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As shown in Fig. 7B, 15-LOX-1 expression in A549 cells required a minimum of 11 hours 
continuous exposure to IL-4. These data indicate that a single IL-4 stimulus was not sufficient 
to up-regulate expression of the 15-LOX-1 mRNA.  
 
4.1.2  Activation of 15-LOX-1 mRNA expression does not require de novo protein 
synthesis  
As a time lag of 12 h was observed in the start of transcription, it was probable that de novo 
synthesis of additional regulatory factors was required. To test this hypothesis stimulation 
with IL-4 was performed in the presence of cycloheximide (10 µg/ml), a protein synthesis 
inhibitor and the presence of 15-LOX-1 mRNA detected by PCR.  As shown in Fig. 8. 
cycloheximide did not affect the activation of 15-LOX-1  
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or notFigure 8. De novo protein synthesis was not required for induction of 15-LOX-1
mRNA. Cells were exposed to cycloheximide (10 µg/ml) along with IL-4 (670 pM) 
for 12 h. 15-LOX-1 expression was assayed by RT-PCR. IL-4 upregulates histone acetyltransferases in A549 cells 
tion of cellular acetyltransferases may constitute an additional regulatory element in the 
llular signal transduction cascade (Kouzarides, 2000). Acetylation of histones causes 
mational changes of nuclear proteins leading to demasking of potential transcription 
binding sites, so that the transcription factor may bind to the promoter of target genes. 
histone acetylation has recently been implicated in the induction of  15-LOX-1 
sion in CaCo-2 cells (Kamitani et al., 2001), the effect of IL-4 on HAT activity was 
in A549 cells. For this purpose, cells were exposed to IL-4 (670 pM) for 3 h and the 
sates were assayed for HAT activity. IL-4 significantly upregulated HAT activity even 
 relativly short incubation periods (Fig. 9). The HAT activity is the sum of several 
ic processes and involves the activity of various proteins. One of these enzymes is the 
tivating protein CBP/p300, which exhibits a strong HAT activity. To find out whether 
 CBP/p300 was involved in IL-4 induced upregulation of acetyltransferase activity in 
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A549 cells, the cells were transfected with the viral oncoprotein wtE1A, which has been 
identified as an endogenous inhibitor of CBP/p300.  
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synergFigure 9.  IL-4 uprgulates histone acetyl transferase activity via CBP/p300. A549 
cells were exposed to IL-4 for 3 h, and cell lysates were used to measure the histone
acetyltransferase activity. Cells were either untransfected or transfected with the
wtE1A or with its antagonizing mutant E1AmCBP. The experiments were repeated at
least thrice (n = 4).  L-4 treatment the transfected cells exhibited a significantly reduced HAT activity (Fig. 
wever, in cells transfected with E1AmCBP, a mutant of E1A protein incapable of 
g to CBP/p300, no increase in IL-4 induced HAT activity was observed.. These data 
te that the augmented acetyltransferase activity was mainly due to activation of 
300.  
HDACs stimulate IL-4 induced 15-LOX-1 expression  
gree of acetylation of nuclear histones depends on cellular HAT activity but also on the 
y state of histone deacetylases (HDACs). In resting cells there appears to be a steady 
f acetylating and deacetylating events and inhibitors or activators of either process may 
he equilibrium in either direction. Recently, it has been reported that activation of 
 may cause alterations in the chromatin state and may inhibit gene transcription (Kao et 
00). If the hypothesis that CBP/p300 catalyzed histone acetylation is important for IL-4 
d 15-LOX-1 expression) was true, then inhibitors of cellular HDAC are likely to act 
istically to IL-4 or may even be capable of inducing 15-LOX-1 expression in the 
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absence of IL-4. To test this conclusion A549 cells were incubated with suboptimal doses 
(335 pM) of IL-4 in the presence of sodium butyrate (NaBT) and the expression of 15-LOX 
was assayed by Western blotting.  
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 Figure 10. IL-4 synergestically upregulates the expression of 15-LOX-1expression 
by sodium butyrate. Cells were cultured for 24 h in the presence of a suboptimal 
dose of IL-4 (330 pM) alone, 2 mM sodium butyrate (NaBT) alone, or of both
together. The cells lysates were then analyzed for 15-LOX-1 expression using a 
specific antibody. The amount of protein was normalized by Western blotting with β-
actin antibody.  Fig. 10. it can be seen that IL-4 at suboptimal concentration
sion. However, in the presence of NaBT a strong L
tingly, NaBT did also induce 15-LOX-1 expression in th
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may bFigure 12. In vitro binding of transcription factors was dependent on tyrosine
phosphorylation.  A. A549 cells were cultured for 1 and 12 h in the absence or
presence of IL-4 (670 pM). Before starting the incubation, one batch of cells was
pretreated with genistein (25 µg/ml) for 15 min. After the incubation period, cells
were harvested, nuclear extracts were prepared, and DNA binding assays were
performed. First lane, cells incubated for 12 h in the absence of IL-4; second lane, 
cells incubated for 1 h in the presence of IL-4; third lane, cells incubated for 12 h in 
the presence of IL-4; fourth lane, genistein-pretreated cells incubated for 12 h in the 
presence of IL-4. pected STAT6 was one of the major components and its identity was confirmed by 
rn blots using commercially available anti-STAT6 antibodies (fig. 11). Interestingly, 
ttern of the binding proteins was very similar when cells were treated with IL-4 for 1 or 
urs (Fig. 11, lane 2 and 3). These data indicate that under in vitro conditions the 
iption factors including STAT6 are capable of binding to the immobilized 15-LOX-1 
ter and that 1 h incubation was sufficient for maximal in vitro binding. Combining 
data (rapid in vitro binding) with the results shown in Fig. 7 (delayed 15-LOX-1 
sion) one may conclude that in vivo the binding of phosphorylated STAT6 to the 
ter was hindered. Alternatively, co-activators exhibiting a prolonged time-dependence 
e required for transcriptional regulation of the 15-LOX-1 gene.  
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It has been reported for other cell types that tyrosine phosphorylation was involved in IL-4 
and IL-13 induced 15-LOX-1 expression (Conrad and Lu, 2000). Thus, the effect of genistein, 
a potent tyrosine kinase inhibitor, on protein phosphorylation and on the binding activity of 
nuclear proteins to the 15-LOX-1 promoter was examined. A549 cells were treated with 
genistein (25 µg/ml) for 30 min. After washing away the inhibitor 670 pM IL-4 was added 
and the cells were cultured for additional 12 hours. Subsequently, the nuclear extracts were 
analyzed for the presence of 15-LOX-1 promoter binding proteins. From Fig. 12 (lane 4) it 
can be seen that genistein completely blocked the binding of proteins to the promoter and 
abrogated 15-LOX-1 expression (Fig. 13). Similarly treated cells were also analysed for the 
presence of acetylated STAT6. Genistein was observed to inhibit IL-4 induced acetylation of 
STAT6 (Fig. 13).  
 
 Blank                    IL-4         Genistein + IL-4
Acetyl STAT6 
15-LOX-1 
 
 
 
 
 
 
 
 
Figure 13. Tyrosine phosphorylation of STAT6 was important for 15-LOX-1 
expression. Cells were treated with IL-4 for 12 h with or without preincubation with 
genistein. The proteins were assayed for acetyl STAT6 and 15-LOX-1 by Western 
blotting. 
 
 
 
These data suggests that tyrosine phosphorylation in A549 cells was a prerequisite for STAT6  
acetylation and binding to the 15-LOX-1 promoter. 
 
4.1.6 In vivo binding of STAT6 and histones to the 15-LOX-1 promoter 
From Fig. 12, it was concluded that under in vitro conditions phosphorylated STAT6 was 
capable of binding to the 15-LOX-1 promoter. The next series of experiments were aimed at 
addressing the question of whether or not such a binding may actually occur in vivo. For this 
purpose A549 cells were cultured in the presence of IL-4 for various time periods and DNA 
binding proteins were cross-linked to the nucleic acid by formaldehyde treatment. Then 
STAT6 was immunoprecipitated with a specific antibody and the cross-linked DNA was 
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analysed by PCR using 15-LOX-1 promoter specific primers. We found that the earliest 
binding of STAT6 was detected after 11 hours of IL-4 exposure (Fig. 14). These data were 
somewhat surprising since both STAT6 phosphorylation and its in vitro binding were rapid 
processes. Thus, it was concluded that the binding of STAT6 to the 15-LOX-1 promoter in 
vivo was hindered during early phases of the incubation period.  
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 Figure 14. Differential kinetics of in vivo binding of STAT6, histone, and 
acetylated histone to the 15-LOX-1 promoter. A549 cells were exposed to IL-4 
(670 pM) for the periods indicated and then treated with formaldehyde to cross-link 
DNA binding proteins to the DNA. The protein-nucleic acid complexes were 
immunoprecipitated with anti-STAT6, anti-histone H3, and anti-acetylhistone H3 
antibodies. The cross-linked DNA was purified and analyzed by PCR for the presence 
of 15-LOX-1 promoter DNA. An aliquot of the complexes was removed before the
immunoprecipitations and was similarly processed and used as a control for the PCR
reaction. This DNA was referred to as input chromatin. r in vivo binding studies were performed using anti-histone H3 (middle lane) and anti-
istone H3 antibodies (lower lane). It was observed that non-acetylated histones were 
 at the early phase of the induction process. In contrast, STAT6 and acetylated histones 
ound exclusively at later stages. These data indicate an inverse correlation between the 
g of non-acetylated histone and the activation of 15-LOX-1 gene.  
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4.1.7 STAT6 and histones physically interact in the acetylated form 
Immunoprecipitations were performed to obtain experimental evidence for a physical 
interaction between STAT6 and histones upon IL4 stimulation. To check for in vivo 
interaction, the cells were treated with 1% formaldehyde to crosslink the proteins and then 
immunoprecipitation was performed on the protein extract and then a dual 
immunoprecipitation strategy was carried out. After the first immunoprecipitation with the 
anti-acetylhistone H3 antibody the protein was divided into 2 lots. The majority (75%) was 
used for the second round of immunoprecipitation with STAT6 antibody and western blotting 
using an anti-acetyl antibody as probe. This laborious method had to be applied since no 
antibody against acetyl STAT6 was currently available. For immunostaining of the 
acetylhistone H3 only 25% of the initial immunoprecipitate was used because of its 
abundance in the cell. This strategy as well as the different cross-reactivity of the anti-acetyl 
antibody with different acetylated proteins does not allow a direct comparison of the relative 
amounts of STAT6 and histones H3. At 11 hours after IL4 stimulation, acetyl STAT6 was 
bound to the acetyl histones while at 4 hours very little of this interaction was observed (Fig. 
15).  
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 Figure 15. Interaction between acetyl STAT6 and acetyl histones. Cells were 
exposed to IL-4 for 4 and 11 h, and DNA-binding proteins were cross-linked to the 
DNA by formaldehyde treatment. Cross-linking was reversed and the proteins were 
analysed by Western blotting for acetylhistone H3 and acetyl STAT6. observation was in accordance with the data obtained from the chromatin 
oprecipitaion experiments (Fig. 14). Further, after the reversal of crosslinking, the 
immunoprecipitaion was performed with STAT6 antibody and similar results were 
ed. Here again, an increased binding of acetyl STAT6 to acetylhistones H3 during the 
ourse of IL-4 treatment was observed (Fig. 16, left panel).  
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 Figure 16.  Kinetics of interaction between STAT6 and histone. Cells were 
incubated with IL-4 for 4 and 11 h, and proteins were cross-linked with formaldehyde.
The proteins were then immunoprecipitated with either Acetyl Histone H3 or STAT6
antibodies. After the reversal of crosslinking, the proteins were analysed by Westrern
blotting for STAT6, acetyl STAT6 and acetyl histone H3. immunoprecipitaion was carried out with a STAT6 antibody, no co-precipitation of 
istones H3 at 4 h of IL-4 exposure but a strong signal after 11 h was observed (Fig. 16, 
anel). The chromatin immunoprecipitation experiments (Fig. 14) showed that after 11 
of IL-4 exposure only acetylated histones H3 and acetylSTAT6 are bound at the 15 
 promoter and the increased binding of acetyl histone to STAT6 during the time course 
4 exposure (Fig. 15) was in line with these data.  
CBP/p300 plays an important role in the acetylation of STAT6 
ylation of STAT6 and of nuclear histones was crucial for IL-4 induced transcription of 
-LOX-1 gene, inhibition of acetylation was expected to block this process. It is known 
he literature that CBP/p300, a transactivating protein with HAT activity, is capable of 
ting STAT6 (McDonald and Reich, 1999). To study the role of CBP/p300, A549 cells 
ransfected with wtE1A and one E1A mutant, which differed from the wild-type with 
t to its functional properties. The mutant E1AmCBP, which lacks amino acids 64-68 - 
P binding region - acts as E1A antagonist and does not inhibit the acetyltransferase 
y of CBP/p300 (Hecht et al., 2000). After transient transfection of A549 cells with the 
riate cDNA constructs the cells were treated with IL-4 for 12 h. Cells were harvested, 
and acetylation of STAT6 was measured by Western-blotting using an acetyl-specific 
dy (Fig. 17).  
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Figure 17. CBP/p300 acetylates STAT6. Cells were transfected with either wtE1A, 
E1AmRb or E1AmCBP vector. Cells were then treated with IL-4 for 12 h and protein 
was analysed by Western blot for acetyl STAT6 protein. 
 
 
In cells transfected with wtE1A there was no enhancement in STAT6 acetylation. In contrast, 
cells transfected with the E1AmCBP mutant (E1A antagonist) showed a strong STAT6 
acetylation signal.  
 
 
4.1.9 Acetylation of STAT6 is essential for its promoter binding 
The data shown in the previous figures indicate that STAT6 acetylation was upregulated  
when the cells are stimulated with IL-4 and that the acetyltransferase activity of CBP/p300 
was involved. To find out whether STAT6 acetylation was required for its binding to the 15-
LOX-1 promoter EMSA were carried out. Cells transfected with wtE1A and with the non-
inhibitory mutant E1AmCBP were cultured in the presence of IL-4 for 12 h. The cells were 
then lysed and EMSA was carried out with STAT6 binding consensus sequences. In Fig. 18 it 
can be seen that STAT6 binding occurred when cells were treated with IL-4 and similar 
results were obtained when cells were transfected with the E1A antagonist E1AmCBP, which 
cannot bind CBP/p300 and therefore was unable to inhibit the CBP/p300 acetylase activity. 
On the other hand, no STAT6 binding was observed when acetylation was prevented by 
transfecting the cells with wtE1A.  
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 Figure 18. Acetylation of STAT6 was a prerequisite for its promoter binding.
EMSA was performed with the protein extracts from the wtE1A and E1AmCBP
transfected cells and STAT6 binding element obtained from the 15-LOX-1 promoter.  
 
 CBP/p300 is required for 15-LOX-1 expression 
periments so far have pointed to the importance of CBP/p300 in IL-4 stimulated 15-
 expression. To confirm this effect, different amounts of wt E1A cDNA were 
cted in A549 cells and the cells were stimulated with IL-4. The suppression of 15-
 expression was found to be dose-dependent by both immunoblotting (Fig. 19a) and 
y assays (Fig. 19b).  
0            250       500        750         1000      1500  
ng of wtE1A transfected 
15-LOX-1 Figure 19a. CBP/p300 was essential for 15-LOX-1 expression. Dose dependent 
inhibition of 15-LOX-1 by wtE1A was performed by transfecting cells with varying
amounts of wtE1A (0-1.5 µg) and probing the cell lysates with anti 15-LOX-1 
antibody. 
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activity was determined in the cells by HPLC after treatment with IL-4 for 24h. The 
cell lysates were incubated with AA and lipids were extracted using acidified ethyl
acetate.  13-HODE was used as an internal standard.e latter experiment, cells were transfected with wtE1A and E1AmCBP vectors and 
d with IL-4 for 24 hours. The cell lysate was then incubated with AA, the products 
xtracted and HPLC was performed. Amount of 15-HETE formed was quantitated with 
DE as internal standard. Analysing the 15-LOX activity as a measure for expression of 
ctional protein, similar amounts of hydroxy fatty acids were observed in control cells 
 cells transfected with E1AmCBP (Fig. 19b). In contrast, a significantly reduced 15-
 activity was observed when the cells were transfected with wtE1A.  
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4.2 Induction of apoptosis by 15-LOX-1 
4.2.1 IL-4 causes apoptosis in A549 cells 
15-LOX-1 is a lipid peroxidising enzyme and its expression may cause an increase in the 
cellular concentration of reactive oxygen species and may lead to cell death. To see if IL-4 
stimulation had deleterious effects, A549 cells were examined for apoptosis. TUNEL assay 
showed that IL-4 (670 pM) induces apoptosis in A549 cells after 72 h of stimulation (Fig. 
20a).  
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 Figure 20a. IL-4 causes apoptosis in A549 cells. TUNEL assay was performed after 
incubating A549 cells with IL-4 for 72 h. The right panel shows apoptotic cells stained
blue. The left panel is the untreated cells.in V staining showed similar results (fig. 20b). During the early stages of apoptosis, 
ose their phospholipid membrane asymmetry and expose phosphatidylserine at the cell 
e while the overall structure of the plasma membrane remains intact. Annexin V binds 
cally to phosphatidylserine but cannot penetrate the cell membrane. The exposure of 
atidylserine on the outside of the cell can be monitored using fluorochrome labelled 
in V. The green fluorescent staining of the cell indicates apoptosis. 
Figure 20b. IL-4 causes apoptosis inA549 cells.. A549 Cells were treated with IL-4 
for 72 h and stained with annexin V-fluos. Only the apoptotic cells exhibited 
fluorescence. The control cells (not treated with IL-4) did not show any fluorescent 
staining. 
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4.2.2 IL-4 induces caspase-3 activation via 15-LOX-1 
Next was investigated whether or not caspase-3, a downstream caspase involved in the 
effector phase of apoptosis, is activated when A549 cells were stimulated by IL-4. The 
activity of caspase-3 using DEVD-pNA as substrate showed an increase upon IL-4 stimuation 
and thus confirmed the above findings (Fig. 21). NDGA, a general inhibitor of lipoxygenases 
was used at concentration of 10 µM to verify the effect of 15-LOX-1. A drastic reduction in 
the caspase-3 activity was measured in NDGA treated cells. Furthermore, the  A549 cells 
were treated with 15-HETE (product of 15-LOX-1). 15-HETE (30 µM) produced a similar 
increase in caspase-3 activity as IL-4. Treatment of cells with NDGA before 15-HETE 
incubation did not show any effect on the caspase-3 activity confirming that the product of 
15-LOX-1 was required for caspase-3 activation. 
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 Figure 21. IL-4 induces Caspase-3 activity via 15-LOX-1. Caspase-3 activity was 
measured in A549 cells after incubation with IL-4 and 15-HETE. NDGA was used as 
a lipoxygenase inhibitor to assess the effect of 15-LOX-1 in this process. (n = 3). 
 
 
 
4.2.3 IL-4 induced apoptosis was mediated by 15-LOX-1 
Apoptosis in A549 cells was measured using Cell Death ELISA. This method assays the 
presence of DNA-histone nucleosomal complexes in the cytoplasm, which is an indicator of 
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apoptosis. A549 cells were treated with IL-4 for 72 h, cells were treated with 15-HETE or a 
similar incubation was performed after pre-treatment with NDGA.   
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Figure 22. IL-4 induced apoptosis was mediated by 15-HETE and caspase-3. 
A549 cells were treated with IL-4, 15-HETE or 15-PGJ2 and amount of apoptosis was 
measured by  Cell Death ELISA. NDGA was used to inhibit the 15-LOX-1 enzyme. 
(n = 3). 
 
 
 
 
Figure 22 shows the relative increase in the amount of nucleosomal complexes present in the 
cytoplasm. 15-HETE and IL-4 induced a drastic increase in the amount of apotosis, which 
was inhibited by NDGA pre-treatment. The cells pre-incubated with a peptide inhibitor of 
caspase-3, Z-VAD-FMK (100 µM) also showed complete inhibition of apoptosis confirming 
the central role of caspase-3 in this apoptotic process.  
Similar experiments were performed with Beas-2b cells (fig.23), which represent normal 
tracheobronchial cells. Identical effects were observed in these cells suggesting the process of 
apoptosis by IL-4 was common in both carcinoma and normal cells. 
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Figure 23. IL-4 causes apoptosis in normal tracheobronchial cells. Normal 
bronchial cells were treated with IL-4 and the apoptosis was assayed using Cell Death 
ELISA. (n = 3). 
  
 
 
 
These experiments show the pivotal role of 15-LOX-1 and its product 15-HETE in IL-4 
induced apoptosis in lung cells. 
 
4.2.4 15-HETE is a ligand for PPAR γ  in IL-4-stimulated A549 cells. 
IL-4 treatment of A549 cells results in the upregulation of 15-lipoxygenase, which in turn 
augmented the production of 15-HETE. 12/15 lipoxygenase products have earlier been shown 
to act as ligands for PPARγ at relatively high concentrations. To test the hypothesis that 15-
HETE could serve as a ligand for PPARγ in this cell system, A549 cells were labelled with 
[14C]-arachidonic acid and treated with 670 pM of IL-4 for 72 hours. Total protein extracts 
prepared from the cells were subjected to immunoprecipitation with PPARγ -antibody and 
protein-A agarose. The lipids were extracted from the immune complex and analysed by 
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TLC. In IL-4 treated cells alone a radioactive lipid was observed. It was identified as 15-
HETE by radio-TLC by co-chromatography of standard 15-HETE (Fig. 24).  
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4.2.5 
PPAR
anothe
downsFigure 24. 15-HETE acts as a ligand for PPARγ during IL-4 treatment of A549 
cells. A549 cells radioactively labelled with 14C-AA and were treated with IL-4 and 
the cell lysates were subjected to immunoprecipitation with PPARγ antibody. The 
lipids were extracted from the immunoprecipitates and subjected to TLC to identify
the ligands for PPARγ. ted cells or cells treated with NDGA (10µM) prior to IL-4 challenge failed to show any 
ctive ligand for PPARγ. Thus, 15-HETE produced in A549 cells upon IL-4 stimulation 
 a ligand for PPARγ.  
IL-4 activates PPARγ via 15-HETE 
γ is a nuclear receptor, which upon binding to the ligand gets activated and along with 
r protein RxR binds to a specified sequence element, PPRE, on the promoter of 
tream genes. Binding of the ligand to the receptor is not exclusive to the activation of 
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the downstream targets of the receptor. Thus, ability of 15-HETE to activate PPARγ 
downstream genes was tested utilising a PPARγ driven promoter and luciferase reporter.  
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Figure 25. 15-HETE produced in A549 cells upon IL-4 treatment causes an 
increase in PPARγ dependent promoter activity.  PPARγ dependent promoter 
activation was in A549 cells after transient transfection with a luciferase reporter
vector driven by a PPARγ binding element. The transfection efficiency was
normalised by co-transfection with a CMV driven β-galactosidase control vector. (n = 
3).  
 
 
 
 
IL-4 increased the PPARγ dependent promoter activity (Fig. 25), which was inhibited by 10 
µM NDGA indicating that the enzymatic product of 15-LOX-1 was essential for the promoter 
activation. 15-HETE (30 µM) was also observed to increase PPARγ dependent promoter 
activity, confirming the functional interaction between 15-HETE and PPARγ receptors. A 
similar increase in the luciferase activity was observed with 5 µM 15-deoxy-∆12,14 PGJ2 (15-
PGJ2), a naturally occurring ligand of PPARγ. 
 
4.2.6 IL-4-induced apoptosis was mediated by PPARγ 
Cell Death Detection ELISA detects cytoplasmic DNA-histone complexes indicating 
apoptosis. IL-4 treated cells showed a significant degree of apoptosis as compared to the 
untreated controls. 15-HETE (30µM) and 5 µM 15-PGJ2, a PPAR γ ligand. also caused 
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equivalent percentage of apoptosis when treated for 72 hours. Cells were transiently 
transfected with a dominant negative vector for PPARγ and treated with IL-4. In the PPARγ 
dominant negative vector, PPARγ was leu468 was mutated to Ala and Glu471 was mutated to 
Ala (Adams et al., 1997), which prevented the ability to activate transcription. PPARγ 
dominant negative vector  abolished the induction of apoptosis by IL-4 (Fig. 26).  
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Cell Death ELISA 
Caspase-3 activity assay
  Blank                 IL-4      PPARγDN + IL-4    15-PGJ2   
                                 A549 cells 
Figure 26. IL-4 induced apoptosis via PPARγ. A549 cells were transiently 
transfected with PPARγ dominant negative vector (PPARγDN) and treated with IL-4. 
Apoptosis was measured by Cell Death ELISA and caspase-3 activity assays. (n = 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon treatment of dominant negative cells with 15-PGJ2 no signs of apoptosis were observed. 
This indicated that IL-4 induced apoptosis occurs via PPARγ. Similar results were observed 
with caspase-3 activation too (fig. 26). 
 
4.2.7 PPARγ  upregulates cleavage of caspase-8  
Caspase-8 is one of the important upstream factors involved in the upregulation of caspase-3 
activity. Caspase-8 exists as an inactive 54 kDa molecule which is autocleaved into active 
p41/42 and p18 molecules. A549 cells treated with IL-4 showed significantly higher levels of 
the cleaved products as compared to the untreated cells and cells treated with 10 µM NDGA 
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prior to IL-4 induction (Fig. 27). Similar upregulation of cleavage of caspase-8 was observed 
with 5 µM of 15-PGJ2 and 30 µM 15-HETE.   
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 Figure 27. IL-4 causes cleavage of caspase-8 in A549 cells. A549 cells were treated 
with either IL-4, 15-PGJ2 or 15-HETE. The cell lysates were analysed by Western 
blotting for the cleavage of caspase-8. The major cleavage product is 41 kDa while the 
minor product is 20 Kda, which was too faint to be detected with this antibody. se-8 cleavage was totally abolished in A549 cells transiently transfected with PPARγ 
ant negative vector further emphasising the previous observation (Fig. 28). 
IL-4 apoptosis involves death domain receptor pathway 
domain receptors are family of cell receptors which regulate the survival of the cell in 
se to various factors such as Fas ligand, TNF-α and TRAIL. These receptors upon 
ion utilise special adapter proteins to activate the caspase cascades. The involvement of 
domain receptors in IL-4 and PPARγ induced  apoptosis in A549 cells was verified 
a dominant negative vector of FADD, a vital adapter protein in the signaling cascade. 
utant lacks the death effector domain, thereby is unable to transmit the signal.  
N
Figure 28. IL-
Cells were tran
or FADD. The
cleavage of cas
wn in Fig. 28
cted with FAD
n receptors in IBlank          IL4      PPARγDN   FADDD
Uncleaved Caspase-8
Cleavage product p41
4 induced cleavage of caspase-8 involved death domain receptors. 
siently transfected with the dominant negative vectors of either PPARg
 IL-4 stimulated cell lysates were analysed by Western blotting for the 
pase-8. 
, IL-4 induced cleavage of caspase-8 was completely abolished in cells 
D dominant negative plasmid, demonstrating the involvement of death 
L-4 and PPARγ induced apoptosis in A549 cells. 
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4.2.9 Bid cleavage was not induced by caspase-8 
The activated caspase-8 can stimulate apoptosis via either direct cleavage and activation of 
caspase-3 or the mitochondrial route involving the cleavage of Bid and release of cytochrome 
c into the cytoplasm. 
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Cells 
complFigure 29. Cleavage of Bid does not occur during IL-4 induced apoptosis. No 
cleavage of Bid was observed in IL-4 treated A549 cells indicating the absence of the 
mitochondrial pathway. Jurkat cells treated for 4 h with 25 µM etoposide were used as 
positive control.15-HETE and 15-PGJ2 stimulation failed to induce cleavage of Bid as analysed by 
n blotting (Fig. 29). This suggests that the caspase-8 directly activates caspase-3 upon 
eatment.  As described for type-I cells undergoing apoptosis (Scaffidi et al., 1998). 
 IL-4 treatment causes activation of Bax and downregulates Bcl-XL 
L is an antiapoptotic member of the Bcl-2 family. The anti-apoptotic members of the 
family of proteins reside in the outer membrane of the mitochondria and prevent the 
 of cytochrome c. In the cytoplasm, cytochrome c binds to Apaf1 leading via caspase-9 
activation of caspase-3.  
 
Bcl-XL (~30kDa)
β-actin Figure 30. IL-4 causes downregulation of Bcl-XL in A549 cells. Incubation of A549 
cells with IL-4 causes downregulation of Bcl-XL protein, which was reversed by the 
treatment of cells with NDGA or by the transient transfection of PPARγ dominant 
negative vector.treated w
etely reve15-HETE    A549        IL-4   NDGA+IL-4  PPARγDN + IL-4ith IL-4 showed a marked decrease in the level of Bcl-XL which was 
rsed by the pre-treatment of the cells with NDGA (Fig. 30) and also by the 
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transient transfection of PPARγ dominant negative vector. The effect of IL-4 and PPARγ 
ligands on other members of the Bcl-2 family was investigated. In untreated cells, Bax, a pro-
apoptotic member of the Bcl-2 family, was present mostly in the cytoplasm and upon IL-4 
treatment a large amount was translocated to the mitochondria (Fig. 31). Porin VDAC, a 
mitochondrial membrane protein was used as a control to show the purity of the 
mitochondrial and cytoplasmic preparations. 
 
 
Control cells     Cells + IL-4 
 M        C          M         C
 
Bax
 
 Cytochrome c 
 Porin VDAC 
 
 
Figure 31. Translocation of Bax to mitochondria. Translocation of Bax to 
mitochondria from the cytoplasm was observed upon IL-4 treatment of A549 cells. 
However, no cytochrome c release was observed from the mitochondria upon IL-4 
stimulation. Porin VDAC was used as a control to check the purity of the
mitochondrial preparations. 
 
 
 
 
The decrease in the Bcl-XL levels with the concomitant activation of Bax indicates the 
involvement of the mitochondria in the apoptosis. Regulation by Bcl-2 family of proteins of 
the efflux of cytochrome c occurs by increasing membrane permeability and alteration of the 
inner mitochondrial membrane potential. The released cytochrome c interacts with Apaf-1 in 
the cytoplasm and eventually causes the activation of caspase-3.  However, no cytochrome c 
release was observed upon IL-4 treatment. This implies a cytochrome c-independent 
functional interplay between the pro- and anti-apoptotic members of the Bcl-2 family in IL-4-
induced apoptosis in A549 cells.   
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4.3 12/15-Lipoxygenase exhibits hepoxilin synthase activity 
4.3.1 Rinm5F cells express hepoxilin synthase activity 
Cultured Rinm5F cells were incubated with AA for 20 minutes and the products were 
analysed as ADAM ester derivatives by HPLC monitoring fluorescence detection. As shown 
in Fig. 32, a HXA3 peak was observed, which co-migrated with an authentic standard.  
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 Figure 32. Rinm5F cells synthesise HXA3 from AA. Rin cells were incubated with 
AA, lipids were extracted and derivatised with ADAM reagent. The lipids were
separated on HPLC, the detection was performed at 254 nm. Marked peaks were
ADAM reagent degradation products and do not interfere with the lipid peaks.  longer incubation, e.g. 40 min., HXA3 peak was substantially reduced and a more polar 
ppeared (not shown), which has earlier been characterised as the hydrolysis product 
,11(R),12(S)-trihydroxy-eicosa-5Z,9E,14Z-trienoic acid and 8(S/R),9(R),12(R)-
oxy-eicosa-5Z,8Z,14Z-trienoic acid, trivially known as trioxilins A3 (TrXA3). As these 
ilins are hydrolysed by cellular epoxide hydrolases, HXA3 formation was determined in 
F cells pretreated with 100 µg/ml trichloro-propylene oxide (TCPO), an inhibitor of 
e hydrolases. After 40 minutes incubation with AA a significant increase in HXA3 
ion was observed (Fig. 33) without appearance of a polar peak.  
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 Figure 33. TCPO treatment increases the formation of HXA3. Rin cells were 
incubated with AA, lipds were extracted derivatised and separated on HPLC. TCPO,
an epoxide synthase inhibitor inhibits the formation of trioxilins, thereby increasing
the amount of HXA3 detected. firm the chemical structure of HXA3 from Rinm5F cells, the incubation mixture was 
ted, the residue acid-hydrolysed (to transform HXA3 to stable trioxilins) and converted 
hyl-silyl derivatives for GC-MS analysis. As shown in Fig. 34B (panel II), a single peak 
terising trioxilin A3 (TrXA3) (Fig. 34A) was observed. No TrXB3 was detected, 
ting the absence of HXB3 formation. Heat-denatured (90oC for 10 min.) cell lysate 
to produce any HXA3 from 12-HpETE and no 12-HETE from AA, suggesting an 
atic pathway of formation (Fig. 34B, bottom panel) and the presence of 12-LOX 
y was essential in this process.  
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RIN + 12-HpETE, m/z 243
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Figure 34. Formation of HXA3 in Rin cells. Rin cells were incubated with 12-
HpETE and the extracted lipids were derivatised, separated and identified by GCMS.  
Panel A: Mass spectra of TrXA3 and the fragmentation pattern. 
Panel B: Representative mass chromatogram (m/z 243) of Rin cells and heat
denatured Rin cells reaction with 12-HpETE. 
 
 
 
 
4.3.2 Glutathione peroxidases inhibit the formation of HXA3   
Recently, the prominent role of PHGPx as a 12(S)-HPETE reductase has been demonstrated 
in human platelets (Sutherland et al., 2001). In absence of cGPx the reduction of 12(S)-
HPETE  to 12(S)-HETE was taken over by PHGPx. But, inactivation of both selenoenzymes 
cGPx and PHGPx by the depletion of glutathione, led to accumulation of 12(S)-HPETE, the 
metabolism of which was consequently diverted to HXA3 and HXB3 formation. Since Rinm5F 
cells are almost devoid of cGPx as well as PHGPx (Lortz et al., 2000), the formation of 
hepoxilin was predicted.  
 
RIN (cGPx) + AA, m/z 243
RIN + AA, m/z 243 TrXA3
 
 
 
 
 
 
 
 
Figure 35. Formation of HXA3 was regulated by cGPx. Representative mass 
chromatogram of normal Rin and Rin stably transfected with cGPx and AA.
Transfected cells show no production of TrXA3. B
Results  
 
65
 
As expected these cells synthesised hepoxilin when incubated with AA as substrate (Fig. 35, 
top panel). Conversely, the presence of GPx should diminish the formation of  HXA3. Indeed, 
upon incubation with AA cultured RINm5F cells, stably transfected with cGPx did not 
produce any HXA3 as determined by GC-MS (Fig. 35, bottom panel). Incubation with 12(S)-
HpETE of native or cGPx-transfected RINm5F cells reproduced identical results, to those 
obtained with AA. The chemical characterisation of the hepoxilin by HPLC and GCMS 
showed that only HXA3 and no HXB3 was formed, which another substantiation of the 
enzymatic nature of HXA3 synthesis in Rinm5F cells. 
 
4.3.3 Rat 12/15-LOX exhibits intrinsic HXA3 synthase activity 
Lipohydroperoxidase activity has been attributed to 12/15-Lipoxygenases (Veldink et al., 
1997). This activity suggests a role for 12/15-LOX in the synthesis of HXA3. HeLa cells do 
not exhibit any intrinsic 12-LOX activity, so these cells were utilised for transfection with rat 
12/15-LOX. Upon incubation of cultured transfected cells with AA, neither 12(S)-HETE nor 
HXA3 was produced, suggesting the complete down-regulation of 12-LOX by selenoenzymes 
present in the cell (Fig. 36, top panel).  However, pretreatment of transfected cells with by 2 
mM diethyl maleate (DEM), which depletes cellular glutathione (GSH) and thus inhibits 
glutathione peroxidases (Imai et al., 1998), caused significant enhancement of HXA3 
synthesis (Fig. 36, bottom panel). As no HXB3 formation was detected in GSH- and GPx-
depleted cells, the specific HXA3 synthase activity of 12/15-LOX can be observed. 
 
 
 
 
 
 
 
 
 
 
TrXA3
 
 
 
 
 BAFigure 36. Rat 12/15-LOX exhibits hepoxilin synthase activity. HeLa cells were 
transfected with 12/15-LOX plasmid and reacted with AA.  
Panel A: Hela cells transfected with 12/15-LOX and AA (m/z 243). 
Panel B: HeLa cells transfected with 12/15-LOX and treated with DEM and incubated 
with AA produces TrXA3 (m/z 243). DEM is a glutathione depleting agent. 
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4.3.4 Hepoxilin synthase activity in Rin cells was depleted by a 12/15-LOX antibody 
As seen in the previous experiment, upon 12/15-LOX transfection of HeLa cells hepoxilin 
synthase activity was observed. To confirm these findings, Rin cell lysates were subjected to 
immunoprecipitation with 12/15-LOX specific antibody. The lysate, immunoprecipitate and 
the 12/15-LOX depleted lysate were incubated with 12-HpETE and analysed by GCMS for 
the production of TrXA3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The immunoprecipitated protein shows high amount of hepoxilin synthase activity (fig. 37). 
There was a significant reduction in the hepoxilin synthase activity observed in the Rin cell 
lysate after immunoprecipitaion. Since the amount of protein was higher than the amount of 
antibody complete depletion was not observed. Simultaneously the lipoxygenase activity was 
also determined by the incubation of  lysates with AA and measuring the formation of 12-
HETE produced by HPLC. The depletion in the lipoxygenase activity paralleled the hepoxilin 
synthase activity. 13-HODE was used as an internal standard to normalise the extraction 
process and for quantification. Nevertheless, these observations confirm the hypothesis that 
12/15-LOX was responsible for the hepoxilin production. 
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Figure 37: 12/15-LOX antibody depletes hepoxilin synthase activity from RIN
cells.  Rin cell lysate was subjected to immunprecipitation with 12/15-LOX antibody. 
The total lysate, immunoprecipitate and the depleted lysate were incubated with 12-
HpETE and the production of TrXA3 was measured by GCMS. Similarly 
lipoxygenase activity was determined by incubating the lysates with AA and analysing 
with HPLC. 13-HODE was used as internal standard for quantification of both TrXA3
and 12-HETE. (n = 3). 
Hepoxilin synthase activity  
Lipoxygenase activity 
  Total cell lysate     Immunoprecipitate    Depleted lysate 
Results  
 
67
 
4.3.5 Recombinant 12/15-LOX protein exhibits hepoxilin synthase activity 
The full length 12/15-LOX gene was amplified from mRNA prepared from RIN cells. The 
PCR product was cloned into pET15b bacterial expression vector. E.coli BL21 DE3 cells 
were transformed with this vector and the recombinant protein synthesis was induced by 1 
mM IPTG for 3 hours.  
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minutesFigure 38: Recombinant 12/15-LOX exhibits hepoxilin synthase activity.
Recombinant 12/15-LOX was expressed in bacteria. The bacterial lysate was reacted
with 12-HpETE. The extracted lipids were derivatised with ADAM reagent and
separated by HPLC. The recombinant enzyme produces a clear HXA3 peak. 
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The cell lysate was incubated with 12-HpETE and the extracted lipids were subjected to 
HPLC. A distinct HXA3 peak was observed (fig. 38). This experiment confirms the hepoxilin 
synthase activity of 12/15-LOX. 
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4.3.6 12/15-LOX produces epoxyhydroxy compounds with 15(S)-HpETE 
To test whether the lipohydroperoxidase activity of 12/15-LOX was applicable to other 
substrates, 15(S)-HpETE was reacted with the recombinant enzyme. The GCMS 
chromatogram shows the production of two compounds which were identified as 11,12,15-
trihydroxyeicosatrienoic acid and 11,14,15-trihydroxyeicotrienoic acid (THETA) (fig. 39). 
Identical compounds were identified in reaction of rabbit 15-LOX and AA (Pfister et al., 
1998). Furthermore, 15-LOX did not produce any epoxyhydroxy compounds with 12-HpETE. 
Thus, rabbit 15-LOX appears to use only 15-HpETE as substrate while rat 12/15-LOX can 
accommodate a larger variety of substrates. This unexpected substrate specificity could be due 
the larger predicted active site volume in the 12/15-LOX as compared to the rabbit 15-LOX. 
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Figure 39: Rat 12/15-LOX produces epoxyhydroxy compounds from substrates
other than 12-HpETE.  
Panel A: Representative mass chromatogram (m/z 243) for the reaction between
recombinant rabbit 15-LOX and 12-HpETE. No TrXA3 was detected. Panel B:
Chromatogram (m/z 173) of 15-LOX and AA. Panel C: Chromatogram (m/z 173) of 
rat 12/15-LOX with 15-HpETE. In panel B and C formation of compound I and II 
were observed. The fragmentation profile of the two compounds allowed their
identification as I : 11,14,15-THETA and II: 11,12,15-THETA. 
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 rat 12/15-LOX        rabbit 15LOX     15LOX - I418A mutant       
 
Figure 40. Positional determinant of 12-Lipoxygenation reaction is important for 
the hepoxilin synthase activity. Recombinant rat 12/15-LOX, wild type rabbit 15-
LOX and I418A mutant of 15-LOX were incubated with 12-HpETE and the products 
were analysed by GCMS. TrXA3 formation was quantified by comparison to the
internal standard (15-HETE). (n = 3). 
 
 
 
 
The mutation of isoleucine 418 to alanine (I418A) in rabbit 15-LOX was observed to shift the 
positional specificity of this towards 12-lipoxygenation (Sloane et al., 1991). Formation of 
TrXA3 was measured with recombinant rat 12/15-LOX, wild type rabbit 15-LOX and I418A 
mutant of 15-LOX. As observed before (fig. 39) wild type 15-LOX did not produce any 
TrXA3 with 12-HpETE, however, the I418A mutant showed a substantial increase in the 
formation of TrXA3 (fig. 40). This demonstrates the importance of the positional specificity of 
the 12-lipoxygenase reaction for the hepoxilin synthase activity. These data attest the 
hypothesis that 12/15-LOX possess a hepoxilin synthase activity and can accommodate 
different substrates like 12-HpETE and 15-HpETE.  
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5. Discussion 
5.1 Upregulation of 15-LOX-1 expression by IL-4 in lung epithelial cells   
Acetylation of proteins is a common principle to modify their biological activity. It impacts 
protein chemical properties and, thus may alter protein-protein interaction, DNA recognition 
and protein stability. Histones were the first proteins that have been identified as targets for 
protein acetylation. Although there are several lines of experimental evidence suggesting the 
importance of histone acetylation in the transcription of a variety of genes (Grunstein, 1997), 
its precise role in nucleosome remodelling is still elusive. Several families of histone 
acetyltransferases (PCAF/GCN5, CBP/p300, TAF(II)250, SRC-1, MOZ) have been 
characterized in the past and, recently even non-histone nucleic acid binding proteins, such as 
HMG-1, p53, GATA1 have been identified as acetylation substrates (Sterner et al., 1979; Gu 
and Roeder, 1997). The consequence of acetylation of these regulatory proteins depends on 
the internal sites of acetylation. For instance, HMG-1 is acetylated at its DNA binding site, 
which results in the disruption of its DNA-binding capabilities (Sterner et al., 1979). In 
contrast, other transcription factors such as p53, GATA1, E2F1 are acetylated outside their 
DNA binding site and this results in stimulation of DNA-binding (Gu and Roeder, 1997). 
Sequence alignments have indicated that STAT6 contains several potential acetylation sites 
and its acetylation has already been reported before (McDonald and Reich, 1999). However, 
this process was independent of IL-4. The data presented in this study clearly indicate that IL-
4 induced transcription of the 15-LOX-1 gene requires upregulation of STAT6 acetylation, 
which is mainly due to activation of the acetyltransferase activity of CBP/p300. It should, 
however, be stressed that the acetylation degree of cellular proteins is a resultant of 
acetylating and deacetylating processes. Thus, an increase in the acetylation degree of STAT6 
can either be achieved by activation of acetyltranferases (CBP/p300) and/or by inhibition of 
deacetylases. Deacetylases have been shown to occur in the nucleus and appear to play an 
important role in transcriptional repression (Downes et al., 2000). Whether they are recruited 
by nuclear hormone receptors bound to certain nuclear corepressors is not clear (Ordentlich et 
al., 2000). It was found that sodium butyrate (non-specific inhibitor of cellular HDAC) alone 
is capable of inducing 15-LOX-1 expression in A549 cells suggest that transcriptional 
repression of the 15-LOX gene in resting cells may be due to a preponderance of 
deacetylating processes over acetyltransferases. It would be of particular interest to elucidate 
whether it is a general principle for transcriptional repression of 15-LOX-1 gene in 
mammalian cells. Recently, Kamitani et al., 2001, have observed that treatment of colorectal 
cell line, Caco-2 with sodium butyrate and other histone deacetylase inhibitors causes an 
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upregulation of 15 LOX-1 expression and found that this upregulation is linked to the degree 
of histone acetylation. Recently, the expression of IL-8 gene by lung epithelial cells upon 
challenge by particulate matter was also shown to be upregulated by histone acetylation 
(Gilmour et al., 2003). Moreover, the question of whether similar mechanisms may be 
involved in transcriptional activation of other IL-4-inducible genes remains to be investigated 
in the future. 
In A549 cells the expression of the 15-LOX-1 gene may be inhibited under resting conditions 
because non-acetylated histones formed by HDAC are bound to the 15 LOX-1 promoter. This 
mode of transcriptional repression has been reported for a variety of inducible genes and 
appears to be well characterised (Grunstein, 1997). Histone binding to genomic DNA forms a 
condensed nucleosomal structure and there is no possibility for the binding of specific 
transcription factors. Acetylation may induce conformational changes of the histone octamer, 
which then may provide access to transcription factors for binding to the promoter of relevant 
genes. Originally, it was postulated that phosphorylation of STAT6 would be sufficient to 
allow its binding to the 15-LOX-1 promoter. However, the present data indicates that this may 
not be true. In A549 cells IL-4 induces STAT6 acteylation in addition to phosphorylation and 
both reactions appear to be  required for translational activation of the 15-LOX-1 gene. This 
conclusion may be drawn form the following experimental data: i) IL-4 increases the activity 
of cellular acetyltransferases (Fig. 9), particularly of CBP/p300, which are capable of 
acetylating STAT6 (Fig. 17). ii). The viral oncoprotein wtE1A, an inhibitor of 
acetyltransferase activity of CBP/p300, prevented STAT6 acetylation, and expression of the 
functional enzyme. In contrast, its non-inhibitory mutant E1AmCBP was unable to do so (Fig. 
17,18,19). iii) Inhibition of STAT6 acetylation by wtE1A prevented STAT6 binding to the 
15-LOX-1 promoter (Fig. 18). In contrast, the E1AmCBP mutant did not inhibit the 
CBP/p300 acetylase activity and also did not prevent STAT6 binding. iv) The histone 
deacetylase inhibitor sodium butyrate synergistically induced the IL-4-stimulated 15-LOX-1 
expression. 
Since further acetylation of STAT6 by CBP/p300 acetyltransferases takes place inside the 
nucleus, tyrosine phosphorylated STAT6, which is inevitably required for homodimerization 
and subsequent nuclear translocation, becomes an essential precursor. This is strongly 
supported by the inhibition of STAT6 acetylation by genistein (Fig. 11 and 12). No effect of 
wtE1A oncoprotein on the tyrosine phosphorylation of STAT6 was observed as checked with 
anti-phospho-STAT6 antibody in Western blot.  
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Phosphorylation of transcription factors is a rapid process and our in vitro binding assays 
indicated that phosphorylated STAT6 quickly binds to the naked 15-LOX-1 promoter. On the 
other hand, in vivo expression of the 15-LOX-1 mRNA in intact A459 cells requires at least 
11 h and similar observations have been reported for other cytokines (Roy and Cathcart, 
1998). This obvious discrepancy together with the results presented in Fig. 12 indicated that 
in vivo the binding of phosphorylated STAT6 to the 15-LOX-1 promoter appears to be 
inhibited during the first 11 h of IL-4 treatment. Although the detailed mechanism of the 
inhibitory processes is still unclear our data suggest that the binding of non-acteylated 
histones may be involved. Acetylation of histones, which appears to be a delayed process in 
A549 cells, may overcome this inhibitory process, so that acetylated STAT6 can bind to the 
15-LOX-1 promoter. For the time being, the reasons for the delayed acetylation of histones 
and STAT6 remain obscure. Although the cellular acetyltransferase activity is upregulated 
within 1 h following IL-4 exposure, acetylated histones and acetylated STAT6 could only be 
detected after a 9 h incubation period. 
In summary, it can be concluded from the data that the mechanism of transcriptional 
activation of the 15-LOX-1 gene by IL-4 does not follow the conventional activation pathway 
of IL-4 inducible genes. Acetylation of both histones H3 and STAT6 is essentially required 
for transcriptional activation of the 15-LOX-1 gene, and this acetylation is mainly due to the 
acetyltransferases activity of CBP/p300. These observations suggest that acetylation is an 
additional step required in the normal signal transduction pathway induced by IL-4 in these 
cells. The implication of acetylation in other IL-4 induced pathways, however, needs to be 
confirmed.  
 
5.2 Induction of apoptosis by 15-LOX-1 
In the present study, it has been shown that 15(S)-HETE is bound as a ligand to PPARγ 
transcription factors (Fig. 24) and is an effector of apoptosis (Figs.20-23). Moreover, 
treatment of cells with NDGA, a 15-lipoxygenase inhibitor, prevented the PPARγ activation 
and apoptosis. Identical results were also obtained with PPARγ ligand 15-PGJ2. To further 
substantiate the crucial role of 15(S)-HETE for apoptosis via PPARγ transcription factor, 
dominant negative form of PPARγ was used, in which two amino acids (L468A and E471A) 
have been mutated, thus impairing transcriptional activation and co-factor recruitment 
(Adams et al., 1997). Transfection of PPARγ dominant negative in A549 cells strongly 
inhibited the IL-4-induced and 15-PGJ2-induced apoptosis (Fig. 26), supporting the prominent 
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role of 15(S)-HETE  and 15-PGJ2 as effectors of apoptosis via PPARγ pathway. It must be 
mentioned that the concentrations of 15-HETE (30 µM) and 15-PGJ2 (5 µM) used were far 
higher than the physiological concentrations in the cell. However, this difference should not 
totally discredit the role of the compounds in the apoptotic process as inside the cell the local 
concentrations could attain such values. Experiments with normal bronchial epithelial cells 
BEAS-2B (fig. 23) confirmed the observations in A549 cells and thus underlined the 
importance of these observations in human allergic inflammatory reactions.  
15-LOX-1 is a lipid peroxidising enzyme and has the capability of damaging lipid membranes 
especially the organelle membranes as seen during the maturation of erythrocytes. This entails 
an important role for this enzyme in the process of cell death either through apoptosis or 
necrosis. However, not all LOX expressing cells undergo apoptosis and there is apoptosis in 
the absence of 12/15-LOX. One of the factors with an regulatory role may be PHGPx. The 
ability of PHGPx to scavenge the lipid hydroperoxides may play an important role in limiting 
the damage caused by lipoxygenase. PHGPx has been shown to play an important role in 
inhibiting free radical induced damage of the mitochondria and consequently apoptosis (Imai 
et al., 1996; Nomura et al., 1999). IL-4 treatment of A549 cells causes a simultaneous 
increase in the lipoxygenase activity and a decrease in the PHGPx activity (Schnurr et al., 
1996). This leads to a condition of high oxidative stress and may result in cell death. The 
reduction of the defensive capability of PHGPx could be the decisive step. However, there 
was no cytochrome c release observed upon IL-4 stimulation (fig. 31) indicating a lack of 
mitchondrial membrane leakage and damage. Cytochrome c release is a very rapid process, 
often occurring within the first 30 minutes of the apoptotic process (Lum et al., 2003). Thus 
the release of cytochrome c may have been finished by the time the assay was performed. The 
lipoxygenases constitute only one of a number of pathways operative in the death of a cell. A 
number of other factors, perhaps activated by PPARγ could play a role in the apoptosis 
observed. Thus, the importance of 15-LOX in the apoptotic process needs to be investigated 
in detail.   
The exact downstream processes of PPARγ activation are still unclear. Involvement of death 
domain receptor in IL-4-induced apoptosis has been observed. The application of FADD 
dominant negative vector (Hofmann et al., 2001), lacking the death effector domain, 
abrogated the apoptotic signal induced by IL-4 or PPARγ (Fig. 28) . The involvement of death 
domain receptors in IL-4-induced apoptosis can be observed by the cleavage of caspase-8 to 
active subunits p41/42 and p18 (Fig. 27,28) This cleavage and activation is inhibited by 
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NDGA and PPARγ dominant negative vector demonstrating the vital importance of 15-LOX 
and PPARγ in the activation of apoptosis signal in this cellular system. Activated caspase-8 
has been proposed to stimulate apoptosis through two parallel pathways (Scaffidi et al., 
1998). In type-I cells, capsase-8 directly cleaves and activates caspase-3. Type-II cells utilize 
the mitochondrial pathway through the cleavage of Bid and subsequent release of cytochrome 
c to amplify the apoptotic signal. Caspase-3, an effector caspase further cleaves PARP and 
other cellular proteins to cause apoptosis. The IL-4 treated cells do not exhibit Bid activation 
(Fig. 29), thus suggesting the involvement of the type-I pathway.  Earlier, it has been shown 
that PPARγ promotes the TRAIL induced apoptosis (Ji et al., 2001).  TRAIL utilizes various 
types of death receptors like DR3, DR4 and DR5 to trigger apoptosis (Baker and Reddy, 
1998; Ashkenazi and Dixit, 1998).  However, it is intriguing to note that IL-4-induced 
apoptosis in A549 is mediated simultaneously through two different pathways, i.e. through 
direct activation of caspase-3 and through mitochondrial pathway involving Bax. The 
activation of Bax and its subsequent translocation to the mitochondria along with the decrease 
in Bcl-XL can account for the mitochondrial pathway, however, no cytochrome c release was 
observed. A number of factors other than cytochrome c, when released from the mitochondria 
can activate apoptosis (Garl and Rudin, 1998; Matsuyama and Reed, 2000)  Thus, the 
scenario can be explained in the following way: in type I cell death, binding of 15(S)-HETE 
to PPARγ transcription factor leads to generation of active caspase-8 through activation of 
FADD protein (Fig 27,28), which subsequently activates downstream effector caspase-3. In 
IL-4-stimulated cells the binding of 15(S)-HETE to PPARγ transcription factor downregulates 
Bcl-XL (Fig. 30,31) and the activation of Bax commits the cell to apoptosis via the intrinsic 
pathway. Bax has also been shown to be involved in a number of apoptotic pathways, 
especially the DNA damage-induced apoptosis involving p53 (Wu and Deng, 2002) without 
participation of death receptors. Antidiabetic thiazolidinediones, potent PPARγ agonists, have 
been observed to induce apoptosis in vascular smooth muscle cells through p53 and Gadd45 
pathway, although it is not clear whether PPARγ itself is the effector (Okura et al., 2000). In 
non small cell lung cancer cells, it has been shown that troglitazone induced DNA damage-
inducible Gadd 153 gene. Bax and p53 form an important pathway in DNA damage induced 
apoptosis (Satoh et al., 2002). Caspase-3 has also been observed to activate the intrinsic 
apoptotic pathway by the cleavage of anti-apoptotic Bcl-xL and Bcl-2 to pro-apoptotic 
components (Cheng et al., 1997; Clem et al., 1998). Thus, caspase-3 activated by other 
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pathways can activate the mitochondrial route and provide a positive feedback loop for 
caspase-3 production leading to apoptosis.   
In asthma, an upregulation of IL-4 secretion in the blood and higher levels of 15-HETE in the 
lung and bronchial tissue have been found. It is, therefore, hypothesised that IL-4-induced 
apoptosis is one of the major causes responsible for the hypertrophy of the bronchial smooth 
muscle, denuded surface epithelium, thickened basement membrane and infiltration of 
eosinophils, lymphocytes and mononuclear phagocytes as well as for the apoptotic lesions 
observed in the lung tissue of asthma patients. It has been reported that PPARγ ligands induce 
apoptosis in lung cancer cells, and this may be beneficial for the therapy of such cancers 
(Theocharis et al., 2002; satoh et al., 2002; Inoue et al., 2001; Tsubouchi et al., 2000). In 
contrast, in chronic inflammatory diseases, such as COPD, the loss of alveolar structures in 
the lung tissue due to apoptosis may worsen the lung function (Kasahara et al., 2000). 
 
5.3 Biosynthesis of HXA3 and its regulation by glutathione peroxidases 
Rinm5F rat insulinoma cells, which possess leukocyte-type 12-LOX, are devoid of cGPx and 
PHGPx (Lortz et al., 2000), produced only HXA3 when incubated with AA or 12(S)-HpETE 
(Fig. 32,33). Moreover, no HXA3 was detected in the lysate from heat-inactivated cells (Fig. 
34). But, cultured cells stably transfected with cGPx or PHGPx-cDNA did not show any 
formation of HXA3 (Fig. 35). These results implied the presence of HXA3 synthase-like 
activity in Rinm5F cells and its regulation by glutathione peroxidases. It has been earlier 
reported that 12/15-LOXs exhibit lipohydroperoxide activity and produce epoxyhydroxy 
acids from AA (Veldinck et al., 1997; Kühn, 1996; Kühn et al., 1986a). These reports along 
with other reports on the mechanism of formation of hepoxilin suggested that rat 12/15-LOX 
could be responsible for the hepoxilin synthase activity. To test the hypothesis recombinant 
rat 12/15-LOX was overexpressed in bacteria. This enzyme, upon incubation with 12-HpETE 
or AA, produced HXA3 (fig. 38). Further confirmation was obtained by performing depletion 
experiments with 12/15-LOX specific antibodies, which suggest the cohabitation of hepoxilin 
synthase and lipoxygenase activity in the same protein. Immunoprecipitation with the specific 
antibody depleted the hepoxilin synthase activity in Rin cell lysates (fig. 37) along with the 
LOX activity and the activity was recorded in the immunoprecipitated protein. It must be 
mentioned at this point that immunoprecipitation experiments did not completely deplete the 
enzyme activity in the lysates. It was of interest to test whether the lipohydroperoxidase 
activity could be verified using other substrates. 15-HpETE offered similar structural features 
to test this possibility. Recombinant 12/15-LOX was observed to form two trihydroxy acid 
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(acid hydrolysed from epoxyhydroxy acids) from 15-HpETE. An earlier work (Pfister et al., 
1998) also reported the formation of two trihydroxy acids from AA using rabbit aortic protein 
extracts. These were identified from their fragmentation patterns as 11,12,15 
trihydroxyeicosatrienoic acid (THETA) and 11,14,15-THETA (fig. 39). The fragmentation 
pattern in the case of 12/15-LOX confirmed that the two THETAs were observed with 15-
HpETE as substrate. According to the chemistry of the lipohydroperoxidase reactions, the 
predicted products of such a reaction with 15-HpETE would have been the THETAs. Further, 
recombinant rabbit 15-LOX also produced these compounds with AA. However, when 12-
HpETE was used as substrate with rabbit 15-LOX, no hepoxilin synthesis was observed. This 
suggests that the rat 12/15-LOX has a broader range of substrates as compared to the rabbit 
enzyme. Such a phenomenon could be due the slightly larger predicted volume of the rat 
12/15-LOX active site, which would allow the accommodation of different substrates. 
Furthermore, the shifting of the positional specificity of rabbit 15-LOX to 12-lipoxygenation 
by I418A mutation caused the formation of hepoxilin (fig. 40). This suggests the importance 
of the positional determinants of 12-lipoxygenase reaction for the hepoxilin synthase activity. 
The lipohydroperoxidase activity offers an interesting facet to the enzymatic nature of the 
lipoxygenases. 
HeLa cells overexpressing rat 12/15-LOX did not produce any HXA3 and 12(S)-HETE under 
normal conditions due to the presence of abundant glutathione peroxidases. There was, 
however, a drastic increase in the HXA3 formation upon treatment with DEM, which depletes 
cellular GSH and inhibits PHGPx thus, elevating the overall hydroperoxide tone. These data 
also confirm the hypothesis that the rat 12/15-LOX exhibits an intrinsic HXA3 synthase 
activity. The activity was found to be finely regulated by cellular glutathione peroxidases 
cGPx and PHGPx. This regulation by glutathione peroxidases is in line with earlier 
observations reported for 5-, 12- and 15-LOX (Weitzel and Wendel, 1993; Sutherland et al., 
2001; Schnurr et al., 1996). Normally, in various cell types the presence of glutathione 
peroxidases exerts the primacy of the reduction pathway over the hepoxilin pathway. 
However, in experiments with HeLa cells overexpressing the rat 12/15-LOX seemingly 
selenoenzymes diminished the cellular peroxide tone to such an extent that even a minimum 
peroxide level essential to trigger the activation of 12-LOX may not be present.  
On the basis of these data, it should however be stressed that the mechanism underlying the 
activation of HXA3 synthase activity could be primarily due to competition for the same 
substrate 12-HpETE. Formation of HXA3 implies the removal of hydroperoxides and thus can 
be regarded as a counteraction to the permanent oxidative-stressed cellular status. Thus, 
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synthesis of hepoxilins plays an important role in the processing of cellular hydroperoxides  
and hence in the overall regulation of the 12-LOX pathway in cells deficient in antioxidant 
enzymes.  
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6. PERSPECTIVES 
The central observation in the induction of 15-LOX-1 by IL-4 was the delay in the mRNA 
synthesis. This can be attributed mainly to the kinetics of histone and STAT6 acetylation. The 
exact mechanisms for this process of gene regulation are however not clear. It would be 
interesting to study the kinetics of activation of other transcription factors and co-activators 
and their influence in this process. The expression of 15-LOX-1 is limited to very few cell 
types. This suggests that repressor mechanisms functioning in other cell types preventing the 
expression the enzyme. The next focus of research should be directed at elucidating such 
mechanisms, if at all they exist. This study would be important in understanding the 
mechanisms underlying the expression of 15-LOX-1 and its function in development.  
With the advent of high throughput technology, attempt should be made to study the influence 
of 12/15-LOXs and its metabolites in various tissues and cell types. Automated cDNA micro-
array technology offers such a possibility. This would add to our understanding of the role of 
these enzymes in the basic processes of the cell and shed light on potential roles in clinical 
disorders. Transgenic animals overexpressing 12/15-LOX in specific organs and tissues 
would greatly enhance our knowledge of diseases leading to the development of potential 
therapeutic strategies. 
In this study, the participation of 12/15-LOXs in the apoptotic process in lung cells has been 
observed. PPARγ, a nuclear receptor plays an important role. Though, it is known that 12/15-
LOX metabolites activate this receptor/transcription factor, the downstream targets of the 
factor are not known. The mechanism leading to activation of the death receptor also remains 
to be clarified. Antidiabetic thiazolidonenes are known activators of PPARγ and their 
involvement in the apoptotic process has tremendous therapeutic potential, especially in 
cancer chemotherapeutics. 
Hepoxilins are a novel class of 12/15-LOX metabolites generally observed during the lack of 
or weakening of the antioxidant defence mechanism in the cell. The nature of influence they 
could have in the regulation of pro-oxidant enzymes is another interesting area of research. 
Another interesting aspect of study would be elucidation of the structural aspects of the 
hepoxilin synthase activity. Site-directed mutagenesis studies could be employed to clarify the 
mechanism of action. 
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